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Abstract 40 
The efficacy of angiogenesis inhibitors in cancer is limited by resistance 41 
mechanisms that are poorly understood. Notably, instead of inducing angiogenesis, 42 
some cancers vascularize by the non-angiogenic mechanism of vessel co-option.  43 
Here we show that vessel co-option is associated with a poor response to the anti-44 
angiogenic agent bevacizumab in patients with colorectal cancer liver metastases. 45 
Moreover, we find that vessel co-option prevails in human breast cancer liver 46 
metastases, a setting where results with anti-angiogenic therapy have been 47 
disappointing. In our preclinical mechanistic studies, we show that cancer cell motility 48 
mediated by the Arp2/3 complex is required for vessel co-option in liver metastases 49 
in vivo and that combined inhibition of angiogenesis and vessel co-option is more 50 
effective than inhibiting angiogenesis alone in this setting. Vessel co-option is 51 
therefore a clinically relevant mechanism of resistance to anti-angiogenic therapy 52 
and combined inhibition of angiogenesis and vessel co-option may be a warranted 53 
therapeutic strategy. 54 
 55 
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Introduction 57 
 Metastases can vascularize through sprouting angiogenesis that is stimulated 58 
by vascular endothelial growth factor-A (VEGF-A). This prompted the clinical 59 
development of anti-angiogenic agents, including the VEGF-A targeted antibody, 60 
bevacizumab1,2. Bevacizumab combined with chemotherapy (bev-chemo) can extend 61 
progression-free and / or overall survival in several indications, including metastatic 62 
colorectal cancer (CRC)3,4. Indeed, bev-chemo is now an approved treatment for 63 
many different cancer types, including metastatic CRC. Despite this fact, the survival 64 
benefit achieved with the addition of bevacizumab to chemotherapy is modest, 65 
measured only in terms of months. Moreover, in other indications, including 66 
metastatic breast cancer, anti-angiogenic therapy has yet to demonstrate a survival 67 
benefit in patients5,6. The mechanisms that limit the therapeutic efficacy of anti-68 
angiogenic therapy in patients are still poorly understood.  69 
However, it now emerges that some metastases can also vascularize by the 70 
non-angiogenic mechanism of vessel co-option, a process whereby cancer cells 71 
incorporate pre-existing vessels from surrounding tissue instead of inducing new 72 
vessel growth7-10. Notably, although anti-angiogenic agents (including bevacizumab) 73 
were designed to target sprouting angiogenesis, they were not designed to target the 74 
process of vessel co-option. Because of this, vessel co-option has been suggested 75 
as a potential mechanism of resistance to anti-angiogenic therapy6,10,11. In the current 76 
study, we provide the first evidence that vessel co-option is a clinically relevant 77 
mechanism of resistance to anti-angiogenic therapy in liver metastases and that 78 
combined inhibition of angiogenesis and vessel co-option is more effective than 79 
targeting angiogenesis alone. 80 
 81 
 82 
 83 
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Results 85 
 86 
Replacement growth pattern liver metastases respond poorly to bevacizumab  87 
 The liver is the most common site of involvement in metastatic CRC, and 88 
surgical removal of CRC liver metastases (CRCLMs) is now recommended practice 89 
for eligible patients12. Careful histopathological examination of human CRCLMs has 90 
shown that these tumors can present with three different histopathological growth 91 
patterns (HGPs): the desmoplastic HGP, the pushing HGP or the replacement HGP 92 
(Fig. 1a and Supplementary Fig. 1)8,13. These growth patterns have distinct 93 
histopathological features and utilise different mechanisms to obtain a vascular 94 
supply. In the desmoplastic HGP, the cancer cells are seperated from the normal 95 
liver parenchyma by a capsule of desmoplastic stroma. In the pushing HGP, there is 96 
no desmoplastic capsule but the cancer cells push the normal liver parenchyma 97 
away. Both of these growth patterns utilise angiogenesis to obtain a vascular supply.  98 
However, in metastases with a replacement HGP, the cancer cells infiltrate the liver 99 
parenchyma and co-opt pre-existing sinusoidal vessels instead of promoting 100 
angiogenesis8,13,14. Although bevacizumab was not designed to target vessel co-101 
option, no study has addressed whether the replacement growth pattern (where 102 
vessel co-option occurs) is associated with resistance to bevacizumab in liver 103 
metastases. 104 
 To address this question, we took advantage of the fact that some patients 105 
with metastatic CRC receive preoperative therapy with bev-chemo in the months that 106 
precede surgical removal of CRCLMs15-17. We evaluated the HGPs and the 107 
pathological response to therapy in 59 CRCLMs resected from 33 patients that were 108 
treated preoperatively with bev-chemo at The Royal Marsden (RM) by examining 109 
haematoxylin and eosin (H&E) stained liver resection specimens (Fig. 1b) (for patient 110 
details see Supplementary Fig. 2 and Supplementary Table 1). Since CRCLMs can 111 
present with a mixture of HGPs13, the percentage of desmoplastic, pushing and 112 
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replacement HGP was quantified in each lesion. To measure response to therapy, 113 
the pathological response in each lesion was scored in quartiles (>75%, 50–75%, 114 
25–49% or <25% viable tumor). Lesions with <25% viable tumor were considered 115 
good responders, whilst lesions with ≥25% viable tumor were considered poor 116 
responders.  117 
Notably, lesions having a substantial (≥50%) replacement component were 118 
significantly enriched in the group of lesions classified as poor responders when 119 
compared to the group of lesions classified as good responders (Fig. 1b, P<0.001). 120 
In contrast, lesions having a substantial (≥50%) desmoplastic component were 121 
significantly enriched in the group of lesions classified as good responders when 122 
compared to the group of lesions classified as poor responders (Fig. 1b, P<0.001). 123 
Similar results were obtained when the same analysis was repeated using only the 124 
single largest lesion from each patient (Supplementary Fig. 3). In a univariate 125 
analysis of other clinical variables, only the HGP showed a statistically significant 126 
association with pathological response (Supplementary Table 2).  127 
Some examples of the lesions examined for this analysis are shown in Fig. 128 
1c–e. In Fig. 1c, a lesion scored as >75% viable with HGP score of 100% 129 
replacement is shown. Note the close contact between tumor cells and liver 130 
parenchyma in the infiltrative replacement growth pattern (arrows). In Fig. 1d, a 131 
lesion scored as <25% viable with HGP score of 100% desmoplastic is shown. Note 132 
the entire circumference of the tumor is desmoplastic and well encapsulated 133 
(arrowheads). A large central area of infarct-like necrosis (ILN), indicative of a strong 134 
treatment response, is labeled (asterisks). In Fig. 1e, a lesion scored as <25% viable 135 
that has a mixed growth pattern (79% desmoplastic, 19% replacement, 2% pushing) 136 
is shown. Note the presence of a desmoplastic rim at the periphery of the tumour 137 
(arrowheads) which surrounds a large central area of ILN (asterisks). However, at 138 
  6
the periphery of the tumour, two viable nodules with a replacement HGP can be seen 139 
(arrows).  140 
To validate the association between the HGPs and pathological response to 141 
therapy, we then examined a larger series of 128 CRCLMs from 59 patients that 142 
were treated preoperatively with bev-chemo at McGill University Health Centre 143 
(MUHC) (for patient details see Supplementary Fig. 4 and Supplementary Table 3). 144 
Again, lesions with ≥50% replacement HGP were significantly enriched in the poorly 145 
responding group of lesions (Fig. 1f, P<0.001), whilst lesions with ≥50% 146 
desmoplastic HGP were significantly enriched in the group of lesions classified as 147 
good responders (Fig. 1f, P<0.001). Similar results were obtained when the same 148 
analysis was repeated using only the single largest lesion from each patient 149 
(Supplementary Fig. 5). In a univariate analysis, the HGP was the strongest predictor 150 
of pathological response (Supplementary Table 4).  151 
Included in these analyses were both patients that presented with a solitary 152 
liver metastasis and patients that presented with multiple liver metastases. To control 153 
for this, we also examined the subset of patients that presented with a single lesion 154 
only (pooled from RM and MUHC). The HGP also correlated with pathological 155 
response in this subset of patients (Supplementary Fig. 6). A univariate and 156 
multivariate analyses of 181 lesions from 90 patients (pooled from RM and MUHC) 157 
was also performed to determine clinical characteristics associated with a good 158 
pathological response (Supplementary Table 5). Only the HGPs showed a 159 
statistically significant association with pathological response. The replacement HGP 160 
was associated with a lower probability of obtaining a good pathological response 161 
(OR=0.07, 95% CI 0.03–0.16, P<0.0001 in univariate and OR=0.06, 95% CI 0.03– 162 
0.15, P<0.0001 in multivariate). In contrast, the desmoplastic HGP was associated 163 
with a higher probability of obtaining a good pathological response (OR=15.06, 95% 164 
CI 6.32–35.87, P<0.0001 in univariate and OR=15.92, 95% CI 6.76–37.51, P<0.0001 165 
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in multivariate). Taken together, these data demonstrate that the replacement HGP is 166 
associated with a poor pathological response to bev-chemo in CRCLMs. 167 
To provide an alternative measure of treatment response, we also evaluated 168 
radiological response in the cohort of lesions from the RM patients. Recently 169 
published guidelines recommend that response to bev-chemo should be evaluated 170 
from computed tomography (CT) scans using novel morphological response criteria 171 
which correlate better with outcome than RECIST-based criteria12,18,19. Lesions with 172 
≥50% replacement HGP were significantly enriched in the poor response group 173 
according to morphological response criteria (Fig. 2; P=0.006). Similar results were 174 
obtained when the same analysis was repeated using only the single largest lesion 175 
from each patient (Supplementary Fig. 7). These data provide independent 176 
verification that CRCLMs with a replacement HGP respond poorly to bevacizumab. 177 
However, notably, no correlation between the HGP and response to therapy was 178 
observed when using RECIST-based criteria as a measure of response 179 
(Supplementary Fig. 8).  180 
 181 
Cancer cells infiltrate the hepatic plates and co-opt sinusoidal blood vessels in 182 
the replacement growth pattern  183 
 We then investigated the mechanism of tumor vascularization in replacement 184 
HGP CRCLMs by examining, in detail, the relationship between cancer cells and the 185 
normal liver in this growth pattern. In normal liver, staining for hepatocyte specific 186 
antigen (HSA) identified hepatocytes within the hepatic plates, whilst collagen-3 187 
staining identified the intervening sinusoidal blood vessels (SV; Fig. 3a). In the 188 
replacement HGP, co-staining for cancer cells (pan-cytokeratin) and hepatocytes 189 
(HSA) demonstrated that invading cancer cells line-up neatly with hepatocytes within 190 
the hepatic plates at the tumor-liver interface  (Fig. 3b). Replacement of hepatocytes 191 
by invading cancer cells was clearly observed (Fig. 3c). Behind the invasive tumor 192 
front, near complete replacement of hepatocytes by cancer cells was evident and 193 
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flattened displaced hepatocytes were frequently observed at the edge of cancer cell 194 
nests (Fig. 3d). However, cancer cells clearly respected the spaces occupied by SV 195 
(Fig. 3b–d). Therefore, in the replacement growth pattern of liver metastasis, cancer 196 
cells (a) invade the liver parenchyma, (b) replace hepatocytes and (c) co-opt SV.  197 
Further evidence for vessel co-option was obtained by staining for the 198 
endothelial marker CD31. In the replacement HGP, SV were frequently observed 199 
where one end of the vessel was physically located in the normal liver (arrows in Fig. 200 
3e–g), whilst the other end was embedded in the tumor (arrowheads in Fig. 3e–g), 201 
showing that these tumors co-opt SV as they infiltrate the liver parenchyma (see also 202 
Supplementary Fig. 9a,b). However, this was not observed in the desmoplastic or 203 
pushing HGPs (Supplementary Fig. 9c–f). In addition, co-staining of tumors for CD31 204 
and HSA demonstrated that tumor vessels at the periphery of replacement HGP 205 
metastases were often still physically associated with hepatocytes, providing 206 
additional evidence that these vessels are co-opted sinusoidal vessels and that they 207 
are not newly formed vessels (Supplementary Fig. 10a,b). However, this was not 208 
observed in the desmoplastic or pushing HGPs (Supplementary Fig. 10c,d). 209 
Therefore, whilst replacement HGP CRCLMs co-opt pre-existing sinusoidal vessels, 210 
the desmoplastic and pushing CRCLMs do not.  211 
 212 
Prevalence of the replacement growth pattern in disease that progresses 213 
following bevacizumab treatment 214 
 Unfortunately, patients can progress following treatment with bev-chemo by 215 
developing new CRCLMs20. Here we define new CRCLMs as lesions that presented 216 
in the liver after the initiation of bev-chemo treatment that were not evident on pre-217 
treatment scans. In our analyses of treatment response described above (Fig. 1) we 218 
only examined resected CRCLMs that were detected on pre-treatment scans prior to 219 
treatment initiation and we specifically excluded any new CRCLMs, even if they were 220 
resected. Given that these new CRCLMs represent progressive disease that is 221 
  9
clearly resistant to bev-chemo, we identified these new CRCLMs and examined their 222 
HGP. In the MUHC case series, 35 new CRCLMs from 13 patients were available for 223 
assessment (for patient details see Supplementary Table 6). We compared the 224 
HGPs in these new CRCLMs with two control groups from MUHC: pre-existing 225 
CRCLMs, i.e. lesions that were resected from bev-chemo treated patients that were 226 
detected on pre-treatment scans prior to treatment initiation (128 CRCLMs from 59 227 
patients; for patient details see Supplementary Table 3) and untreated CRCLMs, i.e. 228 
lesions resected from MUHC patients that did not receive any pre-operative therapy 229 
(32 CRCLMs from 19 patients; for patient details see Supplementary Table 7). The 230 
percentage of tumor scored as having a replacement HGP was significantly 231 
increased in new CRCLMs compared to the CRCLMs in both control groups 232 
(P<0.001, Fig. 4a). This was mirrored by a concomitant significant decrease in the 233 
desmoplastic HGP in new CRCLMs compared to both control groups (P<0.001, Fig. 234 
4a). These data provide evidence for an increased prevalence of the replacement 235 
HGP in patients that progress following treatment with bev-chemo. 236 
 237 
Patients with replacement growth pattern liver metastases achieve less clinical 238 
benefit from bevacizumab  239 
 We then examined whether the HGPs of liver metastasis could impact on the 240 
clinical benefit achieved with anti-angiogenic therapy in terms of patient survival (Fig. 241 
4b-f). Kaplan-Meier estimates of overall survival (OS) were calculated for a cohort of 242 
62 patients from MUHC that were treated preoperatively with bev-chemo between 243 
2008 and 2014 and for a cohort of 29 patients from MUHC that were treated 244 
preoperatively with chemotherapy alone during the same period. Patients were 245 
stratified into groups based on their liver metastasis growth pattern: predominant 246 
replacement HGP,  predominant desmoplastic HGP or predominant pushing HGP 247 
(see Online Methods for details of how these groups were defined).  248 
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 In the bev-chemo cohort, the predominant desmoplastic HGP patients had a 249 
significantly better OS when compared to the predominant replacement HGP 250 
patients (HR=3.50, 95%CI 1.49–8.20, P=0.0022; Fig. 4b). These data suggest that 251 
patients with replacement HGP liver metastases achieve less clinical benefit from 252 
treatment with bevacizumab than patients with desmoplastic HGP liver metastases.  253 
The HGP was the only variable that showed a statistically significant association with 254 
OS in univariate and multivariate analyses (Supplementary Table 8). In addition, both 255 
3-year and 5-year OS were longer for desmoplastic HGP patients compared to 256 
replacement HGP patients in the bev-chemo cohort (Fig. 4f). However, in the cohort 257 
treated with chemotherapy only, no significant difference in OS was observed 258 
between the desmoplastic HGP and replacement HGP patients (HR=0.90, 95%CI 259 
0.31–2.61, P=0.846; Fig. 4c).  260 
 Additional analyses were also performed as follows. Using the same data set, 261 
we examined for a difference in OS between desmoplastic HGP patients that 262 
received chemotherapy alone and desmoplastic HGP patients that received bev-263 
chemo. The difference in OS was not statistically significant (HR=2.49, 95%CI 0.93–264 
6.67, P=0.0605; Fig. 4d). We also examined for a difference in OS between 265 
replacement HGP patients that received chemotherapy alone and replacement HGP 266 
patients that received bev-chemo. Again, the difference in OS was not significant 267 
(HR=0.69, 95%CI 0.27–1.77, P=0.433; Fig. 4e). A comparison of the replacement 268 
group with the desmoplastic group showed that the patients were similar in terms of 269 
their clinical characteristics (Supplementary Table 9). However, the interval between 270 
last dose of therapy and resection tended to be longer in the replacement group 271 
compared to the desmoplastic group (median of 83 days interval for replacement 272 
patients versus 62 days for desmoplastic patients, P=0.030). We also examined for 273 
differences in clinical characteristics between the bev-chemo treated cohort and the 274 
cohort treated with chemotherapy alone (Supplementary Table 10). The cohorts were 275 
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similar except for a larger proportion of patients receiving irinotecan-based 276 
chemotherapy in the bev-chemo cohort compared to the chemotherapy alone cohort 277 
(19% of bev-chemo patients received irinotecan versus 10.3% of chemotherapy 278 
alone patients, P=0.019). 279 
 When stratifying patients based on their liver metastasis HGPs, only two 280 
patients were designated in the predominant pushing group (one patient treated with 281 
bev-chemo and one patient treated with chemotherapy alone). Due to this fact, these 282 
patients were not included in the Kaplan-Meier analysis. However, both of these 283 
patients had a poor outcome because they died within 2 years of diagnosis of liver 284 
metastasis. This is consistent with the findings of a previous study, which showed 285 
that the pushing HGP is an independent predictor of poor overall survival at 2 years 286 
of follow-up21. It is therefore possible that the pushing HGP of CRCLMs is associated 287 
with a poor outcome regardless of the treatment modality utilized. 288 
 289 
The replacement HGP is prevalent in breast cancer liver metastases  290 
Thus far, disappointing results have been obtained with anti-angiogenic 291 
therapy in metastatic breast cancer5,6. Therefore, we also examined the HGPs in 292 
breast cancer liver metastasis samples, obtained from 17 patients, by examining 293 
H&E-stained tissue sections (for patient details see Supplementary Table 11). The 294 
replacement HGP was predominant in 16 of 17 cases examined, with only one case 295 
presenting with a predominant desmoplastic HGP (Fig. 5a). Further histopathological 296 
characterization of replacement HGP BCLMs is presented in Fig. 5b–g. Breast 297 
cancer cells colonized the liver by replacing resident hepatocytes (Fig. 5d) with no 298 
desmoplastic stroma present at the tumor-liver interface (Fig. 5e). The vascular 299 
architecture of the adjacent liver was preserved at the tumor-liver interface (Fig. 5f) 300 
and the co-option of sinusoidal vessels was observed (Fig. 5g). These data show 301 
that the replacement HGP, which vascularizes by vessel co-option, predominates in 302 
breast cancer liver metastases.  303 
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Combined inhibition of vessel co-option and angiogenesis is more effective 304 
than inhibition of angiogenesis alone  305 
 Vessel co-option in the liver requires the infiltration of cancer cells into the 306 
normal liver parenchyma (for example see Fig. 3). We therefore reasoned that 307 
cancer cell motility may be required for vessel co-option. The Actin Related Proteins 308 
2/3 complex (Arp2/3 complex) mediates the nucleation of actin filaments at the 309 
leading edge of cells to drive cell movement, and has been previously implicated in 310 
the motility and invasion of both breast cancer cells and colorectal cancer cells22-24. In 311 
order to confirm expression of the Arp2/3 complex in human liver metastases, we 312 
performed staining for the Arp2/3 subunit ARPC3 using a well-validated antibody. 313 
ARPC3 was expressed in cancer cells in all human specimens we examined. 314 
Moreover, ARPC3 expression was significantly higher in replacement HGP 315 
metastases when compared to desmoplastic HGP metastases (Supplementary Fig. 316 
11).  317 
 To then address whether cancer cell motility mediated by Arp2/3 could play a 318 
functional role in the process of vessel co-option in vivo, we utilized a preclinical 319 
orthotopic model of advanced liver metastasis where HT29 colorectal cancer cells 320 
are directly injected into mouse liver (Supplementary Fig. 12). This model is 321 
commonly used to replicate the advanced stage of CRCLMs where patients are 322 
treated in the metastatic setting25-27. The CRCLMs generated in this model had a 323 
mixed HGP, being mainly composed of replacement HGP areas (Fig. 6a) and, to a 324 
lesser extent, desmoplastic HGP areas (Fig. 6b), thus recapitulating the two 325 
prevalent HGPs observed in human CRCLMs. We then attempted to knock-down 326 
ARPC3 expression in HT29 cells using three different ARPC3-targeting shRNA 327 
oligonucleotides. Two of these oligonucleotides (shARPC3-2 and shARPC3-3) 328 
significantly reduced ARPC3 expression in cells, whereas the third oligonucleotide 329 
(shARPC3-1), and a control non-targeting oligonucleotide (control shRNA), did not  330 
reduce ARPC3 expression in cells (Fig. 6c). In addition, knockdown of ARPC3 331 
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significantly suppressed the migration of HT29 cells (Fig. 6d) without any 332 
confounding effect on cell proliferation (Supplementary Fig. 13). Notably, knockdown 333 
of ARPC3 significantly decreased the replacement HGP in vivo, whilst significantly 334 
increasing the desmoplastic HGP (Fig. 6e). These data confirm that suppression of 335 
Arp2/3-mediated cancer cell motility inhibits the replacement HGP within this in vivo 336 
model and therefore also blocks the ability of these tumors to co-opt pre-existing liver 337 
vessels in vivo. 338 
We then evaluated whether combined inhibition of vessel co-option and 339 
angiogenesis is more effective at limiting tumor growth when compared to 340 
angiogenesis inhibition alone. Mice with established control- or ARPC3-knockdown 341 
tumors were treated with the VEGF-A inhibitory antibody B20-4.1.128 combined with 342 
capecitabine (Fig. 6f–h). In control tumors, which have a predominantly replacement 343 
HGP (Fig. 6f), no significant inhibition of tumor burden was observed in response to 344 
treatment when compared to vehicle control (Fig. 6g). However, in ARPC3 345 
knockdown tumors, which have a predominantly desmoplastic HGP (Fig. 6f), tumor 346 
burden was significantly suppressed by treatment (Fig. 6g). In addition, although 347 
treatment with B20-4.1.1 led to a reduced tumor vessel density in both control- and 348 
ARPC3 knockdown-tumors, this effect was more pronounced when vessel co-option 349 
was suppressed by knockdown of ARPC3 (Fig. 6h, Supplementary Fig. 14). The 350 
administration of capecitabine alone did not significantly suppress tumor burden or 351 
tumor vessel density in either control- or ARPC3-knockdown tumors (Supplementary 352 
Fig. 15). These data suggest that simultaneous inhibition of angiogenesis and vessel 353 
co-option may be a more effective strategy for the treatment of advanced liver 354 
metastases than current strategies which target angiogenesis alone. 355 
  356 
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Discussion 357 
When cancers metastasize to highly vascular organs (including the liver) they 358 
can sometimes utilize vessel co-option, instead of angiogenesis, as a mechanism to 359 
obtain a vascular supply10. Here we addressed whether vessel co-option could be a 360 
significant mechanism of resistance to anti-angiogenic therapy in patients with 361 
colorectal cancer liver metastases. We found that: (a) vessel co-option was the 362 
predominant mechanism of vascularization in approximately 40% of the lesions we 363 
examined, (b) metastases that utilized vessel co-option responded poorly to bev-364 
chemo, (c) vessel co-option was prevalent in patients that progressed following 365 
treatment with bev-chemo, and (d) patients with metastases that utilized vessel co-366 
option obtained less clinical benefit from bev-chemo in terms of overall survival. 367 
These observations strongly suggest that vessel co-option can blunt the therapeutic 368 
benefit achieved with anti-angiogenic therapy in metastatic colorectal cancer. 369 
 Our findings also have relevance for breast cancer. Phase 3 trials of 370 
bevacizumab combined with chemotherapy in metastatic breast cancer have 371 
consistently failed to demonstrate a survival benefit for the addition of bevacizumab29-372 
33. Here we found that the majority of breast cancer liver metastases utilize vessel co-373 
option. In addition, vessel co-option occurs in breast cancer metastases to the lymph 374 
nodes34,35, skin36, lungs7,37,38 and brain39-41. The prevalence of vessel co-option in 375 
breast cancer may explain, at least in part, why anti-angiogenic therapy has been a 376 
disappointing therapeutic approach in metastatic breast cancer.  377 
Biomarkers that are predictive of response to anti-angiogenic therapy in 378 
patients remain elusive6,11,42.  Our data suggest that patients who present with 379 
desmoplastic HGP liver metastases may derive more benefit from bevacizumab than 380 
patients who present with replacement HGP liver metastases, which identifies the 381 
HGPs as potential biomarkers for anti-angiogenic therapy. There are some 382 
characteristics that are present on magnetic resonance imaging (MRI) of the liver, or 383 
CT imaging of the liver, that might be exploited to determine the HGPs of liver 384 
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metastases prior to treatment. By using imaging to identify liver metastasis HGPs in 385 
this way, it may eventually be possible to select-out the patients with desmoplastic 386 
HGP liver metastases who are more likely to benefit from anti-angiogenic therapy.  387 
However, in the longer term, we believe that therapeutic strategies which can 388 
block vessel co-option in tumors should also be developed. In this regard, here we 389 
show that knockdown of Arp2/3-mediated cancer cell motility suppresses vessel co-390 
option in a preclinical model of advanced liver metastasis. Moreover, Kuczynski et al  391 
recently showed that acquired resistance to the anti-angiogenic drug sorafenib in 392 
hepatocellular carcinoma occurs due to increased cancer cell invasion in the liver 393 
which mediates co-option of pre-existing liver vessels43. Taken together, these and 394 
other data44-51, suggest a key role for cancer cell motility and cancer cell invasion in 395 
the process of vessel co-option and that targeting cancer cell movement might, 396 
therefore, be an effective means to block vessel co-option in tumors.  397 
In the current manuscript, we also present preclinical evidence that combined 398 
inhibition of angiogenesis and vessel co-option is more effective at controlling tumor 399 
burden than targeting angiogenesis alone. We propose therefore that therapies 400 
which are designed to inhibit both angiogenesis and vessel co-option should be 401 
explored in patients, as these may yield greater therapeutic benefit than current 402 
therapies that are designed to target angiogenesis alone.  403 
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Figure legends 618 
 619 
Figure 1 Correlation between HGP and pathological response in patients 620 
treated preoperatively with bevacizumab 621 
a. Diagrams illustrating the morphology of the normal liver or the morphology of the 622 
tumor-liver interface in liver metastases with a desmoplastic, pushing or replacement 623 
HGP. b. The HGPs and the pathological response to bev-chemo were scored in 59 624 
CRCLMs from 33 patients treated preoperatively with bev-chemo at RM. Graph 625 
shows % HGP (replacement, desmoplastic, pushing) scored in each individual lesion 626 
and the data are grouped by pathological response score: >75%, 50–75%, 25–49% 627 
or <25% viable tumor. Median number of lesions examined per patient was 1 (range 628 
= 1 to 4 lesions per patient). c–e. Examples of H&E-stained lesions from the RM 629 
cohort are shown. Arrows point to examples of replacement HGP areas. Arrowheads 630 
point to examples of desmoplastic HGP areas. Asterisks indicate areas of infarct-like 631 
necrosis. f. The HGPs and the pathological response to bev-chemo were scored in 632 
128 CRCLMs from 59 patients treated with bev-chemo at MUHC.  Graph shows % 633 
HGP (replacement, desmoplastic, pushing) scored in each individual lesion and the 634 
data are grouped by pathological response score: >75%, 50–75%, 25–49% or <25% 635 
viable tumor. Median number of lesions examined per patient was 2 (range = 1 to 12 636 
lesions per patient). The χ2-test was used to determine statistical significance (see 2 637 
x 2 contingency tables in panels b and f). Scale bars, 1 mm.  638 
 639 
 640 
641 
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Figure 2 Correlation between HGP and morphological response on CT in 642 
patients treated preoperatively with bevacizumab 643 
a–f. CT scans of patients treated preoperatively with bev-chemo. Examples of 644 
optimal (OR), partial (PR) or absent (AR) morphological response are shown.  645 
a,b. OR; in the pre-treatment image a lesion in liver segment VII (arrowhead) is 646 
scored as group-3 (a); the same lesion imaged after 4 cycles of bevacizumab in 647 
combination with CAPOX is now scored as group-1 (b).  648 
c,d. PR; in the pre-treatment image a lesion in liver segment II (arrowhead) is scored 649 
as group-3 (c); the same lesion imaged after 4 cycles of bevacizumab in combination 650 
with CAPOX is now scored as group-2 (d). 651 
e,f. AR; in the pre-treatment image a lesion in liver segment VI (arrowhead) is scored 652 
as group-3 (e); the same lesion imaged after 6 cycles of bevacizumab in combination 653 
with FOLFIRI is still scored as group-3 (f). 654 
g. Morphological response and HGP were scored in 52 liver metastases from 31 655 
patients treated preoperatively with bev-chemo at RM. Graph shows the % HGP 656 
scored in each individual lesion (replacement, desmoplastic, pushing). Lesions are 657 
grouped according to response: AR, PR or OR. Lesions scored as AR were classed 658 
as poor responders, whilst those scored as PR or OR were classed as good 659 
responders. Median number of lesions examined per patient was 1 (range = 1 to 4 660 
lesions per patient). The χ2 test was used to determine statistical significance (see 2 661 
x 2 contingency table in panel g).   662 
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Figure 3 Cancer cells infiltrate the hepatic plates and co-opt sinusoidal blood 663 
vessels in the replacement HGP 664 
a. An area of normal liver is shown. Staining is for hepatocyte specific antigen (HSA, 665 
green) to detect hepatocytes and collagen-3 (col-3, red) to detect liver sinusoidal 666 
blood vessels (SV). b–d. Staining for cancer cells (CK, red) and hepatocytes (HSA, 667 
green) at the tumor-liver interface (b,c) and within the tumor mass (d) in a 668 
replacement HGP liver metastasis of colorectal cancer. Examples of displaced 669 
hepatocytes are marked (arrowheads). e–g. Staining for cytokeratin 20 (CK20, 670 
brown) to identify cancer cells and CD31 to identify blood vessels (blue) in 671 
replacement HGP liver metastases of colorectal cancer. Arrows and arrowheads 672 
indicate examples of liver sinusoidal blood vessels where one end of the vessel is 673 
physically located in the liver parenchyma (arrows), whilst the other end is 674 
surrounded by cancer cells (arrowheads). Asterisk, tumor. Lv, normal liver. SV, 675 
sinusoidal blood vessel. Scale bars, 25 μM.  676 
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Figure 4 The replacement HGP occurs in progressive disease and is 678 
associated with a poor outcome in patients treated with bevacizumab 679 
a. Left: HGPs in untreated CRCLMs (n = 32 lesions from 19 MUHC patients).  680 
Middle: HGPs in pre-existing CRCLMs (n = 128 lesions from 59 MUHC patients). 681 
Right: HGPs in new CRCLMs (n = 35 lesions from 13 MUHC patients). Graphs show 682 
% replacement (R), % desmoplastic (D) and % pushing (P) HGP per lesion ± SEM. 683 
b. Kaplan-Meier estimates of OS for 62 MUHC patients treated preoperatively with 684 
bev-chemo stratified into two groups: predominant replacement HGP (26 patients) or 685 
predominant desmoplastic HGP (35 patients). c. Kaplan-Meier  estimates of OS for 686 
29 MUHC patients treated preoperatively with chemotherapy alone stratified into two 687 
groups: predominant replacement HGP (12 patients) or predominant desmoplastic 688 
HGP (16 patients). d. Kaplan-Meier estimates of OS for 51 MUHC patients with a 689 
predominant desmoplastic HGP stratified into two groups: desmoplastic HGP treated 690 
with bev-chemo (35 patients) or desmoplastic HGP treated with chemotherapy alone 691 
(16 patients). e. Kaplan-Meier estimates of OS for 38 MUHC patients with a 692 
predominant replacement HGP stratified into two groups: replacement HGP treated 693 
with bev-chemo (26 patients) or replacement HGP treated with chemotherapy alone 694 
(12 patients). Kruskall-Walls test (a) or the Log-Rank test (b–e) were used to 695 
determine statistical significance. Hazard ratios were calculated using Cox-696 
regression. * P<0.001.  697 
 698 
  699 
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Figure 5 The replacement HGP predominates in breast cancer liver metastases 700 
a. The HGPs were examined in breast cancer liver metastases (BCLMs) from 17 701 
patients. Graph shows the % HGP (replacement, desmoplastic, pushing) scored in 702 
each case. The cases are grouped by intrinsic subtype of breast cancer. Lum A, 703 
luminal A. Lum B (HER2-), luminal B HER2 negative. Lum B (HER2+), luminal B 704 
HER2 positive. TN, triple negative.  705 
b–g. Morphology of the replacement growth pattern of BCLMs. Diagram of the 706 
tumor-liver interface in the replacement HGP (b). H&E-stained human BCLM sample 707 
illustrating the tumor-liver interface (c). Co-staining for hepatocyte specific antigen 708 
(HSA) to label hepatocytes and pan-cytokeratin (CK) to label cancer cells confirms 709 
that breast cancer cells infiltrate the liver parenchyma and replace hepatocytes in 710 
BCLM (d). Co-staining for alpha smooth muscle actin (αSMA) to label fibroblasts and 711 
CK to label cancer cells confirms the absence of a desmoplastic stroma at the tumor-712 
liver interface in BCLM (e). Co-staining for collagen-3 (col-3) to label sinusoidal 713 
vessels and CK to label cancer cells shows that the vascular architecture of the 714 
adjacent liver is preserved at the tumor-liver interface in BCLM (f). Co-staining for 715 
CD31 to label blood vessels and cytokeratin 19 (CK19) to label cancer cells confirms 716 
the infiltrative pattern of tumor growth that facilitates vessel co-option in BCLM (g). 717 
Asterisk, cancer cells; Lv, normal liver. Scale bars, 50 μM. 718 
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Figure 6 Inhibition of vessel co-option and angiogenesis is more effective than 720 
targeting angiogenesis alone 721 
a,b. Areas of replacement (a) and desmoplastic (b) HGP are shown in a preclinical 722 
(HT29 cell line) orthotopic model of advanced liver metastasis. Staining shown is for: 723 
H&E, CK and HSA, CK and col-3, CK and αSMA or cytokeratin 20 (CK20) and 724 
CD31, as indicated. c,d. Characterization of parental HT29 cells (parent) and HT29 725 
cells transduced with control non-targeting shRNA (control shRNA) or ARPC3-726 
targeting shRNAs (shARPC3-1, shARPC3-2 or shARPC3-3). In c, ARPC3 727 
expression was determined by western blotting (see also Supplementary Data Set 728 
1). Graph shows ARPC3 expression relative to parental HT29 cells ± SEM  (n = 3 729 
independent western blots). In d, cell motility was measured by time-lapse 730 
microscopy. Graph shows cell velocity (μm per minute) relative to parental HT29 731 
cells ± SEM  (n = 30 tracked cells per group pooled from 2 independent 732 
experiments). e. Quantification of the HGPs in control- and ARPC3-knockdown 733 
tumors. Graph shows the % replacement (R), % desmoplastic (D) and % pushing (P) 734 
HGP per group ± SEM (n = 6 mice per group). f–h. Tumors with normal ARPC3 735 
levels (control shRNA) or ARPC3 knockdown (shARPC3-3) were established in the 736 
livers of mice, followed by treatment with B20-4.1.1 plus capecitabine (BC) or vehicle 737 
alone (Vh) for two weeks followed by histopathological analysis. Graph in f shows the 738 
% HGP per group ± SEM (n = 8 mice per group). Graph in g shows liver tumor 739 
burden expressed in terms of lesion area ± SEM (n = 8 mice per group). Graph in h 740 
shows tumor vessel density in terms of vessels per mm2 ± SEM (n = 8 mice per 741 
group). For statistical analysis, Student’s t-test (panels c,g,h) or Mann Whitney U-742 
test (panels d,e,f) were used. *P<0.05, **P<0.01 ***P<0.001, ****P<0.0001. n.s., no 743 
significant difference. Asterisk, cancer cells; DS, desmoplastic stroma; Lv, normal 744 
liver. Scale bars, 50 μM.  745 
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Online Methods 747 
 748 
Human samples 749 
Specimens were obtained from patients treated at The Royal Marsden (RM) 750 
in London, at McGill University Health Centre (MUHC) in Montreal and at Gasthuis 751 
Zusters Antwerpen (GZA) Hospitals St Augustinus in Antwerp. Informed consent was 752 
obtained from all patients. Ethical approval was granted by the local Research Ethics 753 
Committee at The Royal Marsden, the McGill University Health Centre Research 754 
Ethics Board and by the local Research Ethics Committee of the GZA Hospitals St. 755 
Augustinus.  756 
We identified all cases of CRC liver metastases (CRCLMs) resected from 757 
patients treated preoperatively with a combination of bevacizumab and 758 
chemotherapy (bev-chemo) at RM from 2006-2012 (101 metastases from 47 759 
patients). Of these, 59 liver metastases from 33 patients were eligible for our study 760 
correlating HGP with pathological response. A consort diagram illustrates how these 761 
59 cases were selected for inclusion (Supplementary Fig. 2). For patient 762 
characteristics see Supplementary Table 1. For correlating HGP with morphological 763 
response on imaging, 52 lesions from 31 patients were eligible for inclusion 764 
(Supplementary Fig. 2). For correlating HGP with response by RECIST criteria all 59 765 
liver metastases from 33 patients were eligible for inclusion.  766 
We identified all CRCLMs resected from patients treated preoperatively with 767 
bev-chemo at MUHC from 2008–2014 (191 CRC liver metastases from 65 patients). 768 
Of these, 128 liver metastases from 59 patients were eligible for correlating HGP with 769 
pathological response (Supplementary Fig. 4). For patient characteristics see 770 
Supplementary Table 3. For the analysis of new CRCLMs (i.e. lesions that only 771 
presented after the initiation of bev-chemo but were not present on baseline scans) 772 
we identified 35 resected lesions from 13 patients treated preoperatively with bev-773 
chemo at MUHC (Supplementary Fig. 4). For patient characteristics see 774 
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Supplementary Table 6. A total of 148 liver metastases from 62 patients treated 775 
preoperatively with bev-chemo were eligible for correlating HGP with overall survival. 776 
For the analysis of CRC liver metastases from patients that did not receive pre-777 
operative therapy, we identified 32 lesions from 19 patients at MUHC. For patient 778 
characteristics see Supplementary Table 7. For the analysis of CRCLMs from 779 
patients treated with chemotherapy alone we identified all cases of CRCLMs 780 
resected from patients treated preoperatively with chemotherapy at MUHC from 781 
2008–2014 (81 metastases resected from 30 patients) and from this group a total of 782 
76 liver metastases from 29 patients were eligible for our study correlating HGP with 783 
overall survival. 784 
For breast cancer, all breast cancer liver metastasis cases obtained via 785 
resection or autopsy at GZA Hospitals St. Augustinus from 2004–2015 were 786 
examined (17 patients). For patient characteristics see Supplementary Table 11.  787 
 788 
  789 
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Therapy administration 790 
 Patients receiving treatment with bevacizumab in combination with 791 
chemotherapy were treated with one the following regimens. 792 
 CAPOX plus bevacizumab: 21 day treatment cycle consisting of 15 minute 793 
intravenous infusion of bevacizumab (7.5 mg per kg) and 2 hour intravenous infusion 794 
of oxaliplatin (130 mg per m2) on day one, followed by daily oral capecitabine (1700 795 
mg per m2) in two divided doses from days 1 to 14.  796 
 FOLFOX plus bevacizumab: 14 day treatment cycle consisting of 10 minute 797 
intravenous infusion of bevacizumab (5 mg per kg), 2 hour intravenous infusion of 798 
oxaliplatin (85 mg per m2), 2 hour intravenous infusion of folinic acid (400 mg per m2) 799 
with a bolus dose of 5-FU (400 mg per m2) on day one, followed by 48 hour 800 
continuous intravenous infusion of 5-FU (1200 mg per m2 per day).  801 
 FOLFIRI plus bevacizumab: 14 day treatment cycle consisting of 10 minute 802 
intravenous infusion of bevacizumab (5 mg per kg), 1 hour intravenous infusion of 803 
irinotecan (180 mg per m2), 1 hour intravenous infusion of folinic acid (400 mg per 804 
m2) with a bolus dose of 5-FU (400 mg per m2) on day one, followed by 48 hour 805 
continuous intravenous infusion of 5-FU (1200 mg per m2 per day). 806 
 For patients that received chemotherapy alone, most patients received either 807 
FOLFOX or FOLFIRI administered as described above without the addition of 808 
bevacizumab. However, a minority of patients that received chemotherapy alone 809 
received one of the following regimens instead. 810 
 FOLFIRINOX: 14 day treatment cycle consisting of oxaliplatin (85 mg per m2), 811 
irinotecan (180 mg per m2), leucovorin (400 mg per m2), and 5-FU (400 mg per m2) 812 
followed by a 48 hour continuous intravenous infusion of 5-FU (1200 mg per m2 per 813 
day).  814 
 5-FU: 14 day treatment cycle consisting of leucovorin (400 mg per m2) and 5-815 
FU (400 mg per m2) followed by 48 hour continuous intravenous infusion of 5-FU 816 
(1200 mg per m2 per day). 817 
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 818 
 The decision to administer therapy, the type of therapy and the number of 819 
cycles were based on the recommendation of the local multidisciplinary team. 820 
Patients received oxaliplatin- or irinotecan-based regimens with the addition of 821 
bevacizumab preferentially, as long as there were no contraindications to administer 822 
bevacizumab, such as uncontrolled hypertension, history of gastrointestinal 823 
perforation, history of arterial or venous thromboembolic events, history of significant 824 
bleeding, recent surgery or nephrotic syndrome. In the case that the patient was 825 
deemed unsuitable for administration of bevacizumab, the patient received 826 
chemotherapy alone. 827 
 828 
Scoring HGPs  829 
Sections (5 μm thickness) were prepared from formalin fixed paraffin-830 
embedded (FFPE) liver resection specimens, stained with H&E and then scored for 831 
HGP by two pathologists with extensive experience of scoring the HGPs. In brief, the 832 
tumor-liver interface was categorized as being desmoplastic, pushing or replacement 833 
HGP according to the following criteria. Desmoplastic HGP: there was no direct 834 
contact between cancer cells and liver parenchyma and the cancer cells were 835 
separated from the liver parenchyma by a layer of desmoplastic stroma. Pushing 836 
HGP: close contact between cancer cells and normal liver tissue was observed, 837 
without an intervening desmoplastic stroma. The normal liver was compressed by the 838 
tumor and no invasion of cancer cells into the hepatic plates was observed. 839 
Replacement HGP: close contact between cancer cells and liver parenchyma was 840 
observed, without an intervening desmoplastic stroma. The cancer cells invaded into 841 
the hepatic plates and replaced the hepatocytes without destroying the vascular 842 
architecture of the liver at the tumor-liver interface.  843 
Given that some lesions present with a mixture of different HGPs, the 844 
percentage of the tumor-liver interface with a desmoplastic, pushing or replacement 845 
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HGP was scored in intervals of 5% in all available tissue blocks. Where multiple 846 
blocks were available, the mean average score was calculated to produce a single 847 
score for % desmoplastic, % pushing and % replacement for each lesion.  848 
In some cases, invasion of cancer cells into the hepatic plates (which is a 849 
defining feature of the replacement HGP and required for vessel co-option) was also 850 
accompanied by compression of the liver parenchyma. These cases were scored as 851 
replacement HGP and not pushing HGP. This subtle but important refinement to the 852 
criteria for scoring the HGPs helps to explain why, in the current study, the incidence 853 
of the replacement HGP in CRC metastases is higher than in some previous studies.  854 
 855 
Agreement of HGP scores  856 
 The level of intra-observer and inter-observer agreement for scoring the 857 
HGPs was tested independently. In brief, two pathologists (observers A and B) 858 
scored the HGP (% replacement, % desmoplastic and % pushing) in 150 tissue 859 
sections of resected CRCLM without conferring. After a break of several weeks, the 860 
two pathologists scored the same set of 150 tissue sections again without conferring 861 
and without reference to their previous scores. The % replacement scores from each 862 
round of scoring were then used to test the level of intra- and inter-observer 863 
agreement. The difference between scores is plotted in Supplementary Fig. 16. 864 
 The correlation between scores was calculated using Pearson’s correlation 865 
co-efficient. We also analyzed the data using Bland-Altman plots (Supplementary 866 
Fig. 17) from which we determined the mean difference between the scores and the 867 
limits of agreement (2 standard deviations from the mean difference)52. The results 868 
are tabulated in Supplementary Table 12.  869 
  There was a strong correlation (r > 0.98) between the scores recorded by the 870 
same observer (intra-observer agreement), and also a strong correlation (r > 0.96) 871 
between the scores recorded by the two different observers (inter-observer 872 
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agreement). The Bland-Altman plots showed that the mean difference between the 873 
scores recorded by the same observer was small (0.033 and −0.633) and that the 874 
mean difference between the scores recorded by the two different observers was 875 
also small (−1.500 and −2.167). Taken together, these data indicate that there is a 876 
good level of inter- and intra-observer agreement between observers for scoring the 877 
HGPs.  878 
 Despite this fact, the limits of agreement for the inter-observer agreement are 879 
quite wide (−22.88 to 19.88 and −25.287 to 20.953). This occurred due to the 880 
presence of some cases which have a ‘mixed’ growth pattern that can be more 881 
difficult to score and led to some divergent scores. However, in the main study, in 882 
any cases having a ‘mixed’ growth pattern where there was a significant 883 
disagreement between observers, the two observers were always able to reconcile 884 
their differences in order to produce a single consensus score for the lesion.  885 
 886 
Scoring of pathological response to therapy 887 
For scoring of the pathological response to bev-chemo from H&E-stained 888 
specimens, the extent of viable carcinoma was assessed semi-quantitatively as a 889 
percentage relative to the total tumor surface area. Each lesion was assigned as 890 
belonging to one of four categories: >75%, 50–75%, 25–49% or <25% viable 891 
carcinoma53, with areas of ‘usual necrosis’ being considered part of the viable tumor 892 
fraction, whilst areas of ‘infarct-like necrosis’ were considered to be non-viable54. 893 
Pathological response was scored independently by three experienced pathologists 894 
using these criteria. Any difference in score that occurred between pathologists was 895 
resolved by consensus to produce a single score for each lesion. 896 
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Scoring of morphological response to therapy  899 
Pre- and post-treatment contrast-enhanced CT scans of suitable quality were 900 
available for 52 lesions from 31 patients for this analysis (see consort diagram, 901 
Supplementary Fig. 2) and the response to therapy was evaluated using a method 902 
based on previously published morphological response criteria18,20 as described 903 
below.   904 
The appearance of each lesion on both the pre- and post-treatment scan was 905 
scored as belonging to one of three morphology groups (group-1, group-2 or group-906 
3). A homogeneous, low attenuation lesion with a thin, sharply defined tumor-liver 907 
interface was defined as group-1. A lesion having heterogeneous attenuation and a 908 
thick, poorly defined tumor-liver interface was defined as group-3. A lesion that was 909 
intermediate between group-1 and group-3, having a moderate degree of 910 
heterogeneous attenuation and a moderately defined tumor-liver interface, was 911 
defined as group-2.  912 
Morphological response was defined as an optimal response (OR) if the 913 
lesion changed from a group-3 or group-2 to a group-1 following treatment; a partial 914 
response (PR) if the lesion changed from group-3 to group-2 following treatment; and 915 
an absent response (AR) if the metastasis either did not change group, or went from 916 
group-2 to group-3, following treatment. Morphological response was scored 917 
independently by two observers. Any difference in scores was resolved by 918 
consensus to produce a single score for each lesion. Lesions scored as AR were 919 
considered to be poor responders, whilst lesions scored as PR or OR were 920 
considered to be good responders. Scorers were blinded as to the HGP and 921 
pathological response data.  922 
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Scoring of response by RECIST  924 
Change in lesion size was determined from MRI scan data, by calculating the 925 
change in lesion diameter that occurred between the pre- and post-treatment scans. 926 
The lesion size measurements were obtained from the patient records and were 927 
therefore blinded, because the original reporting radiologist had no prior knowledge 928 
of our retrospective HGP and pathological response data. For this analysis, MRI 929 
scans of suitable quality were available for 59 lesions from 33 patients. Lesions were 930 
classified as partial response (PR), stable disease (SD) or progressive disease (PD) 931 
according to the following criteria: PR (lesion underwent ≥30% decrease in size 932 
between pre- and post-treatment scan), SD (lesion underwent <30% decrease in size 933 
and <20% increase in size between pre- and post-treatment scan) and PD (lesion 934 
underwent ≥20% increase in size between pre- and post-treatment scan).  935 
 936 
Kaplan-Meier estimates of overall survival 937 
Patients were allocated to one of three groups: predominant replacement, 938 
predominant desmoplastic or predominant pushing. To allocate patients to each 939 
group, the mean percentage of replacement, desmoplastic and pushing HGP was 940 
calculated for each patient using the data available from all lesions. Patients with a 941 
mean replacement HGP of >50% were allocated to the predominant replacement 942 
group, patients with a mean desmoplastic HGP of >50% were allocated to the 943 
predominant desmoplastic group and patients with a mean pushing HGP of >50% 944 
were allocated to the predominant pushing group. This method allowed unambiguous 945 
allocation of patients to the three groups (i.e. there were no patients scored as 946 
having a 50:50 score for two growth patterns). Overall survival estimates were 947 
calculated from the date of diagnosis of liver metastases to the date of death or to 948 
the date of last follow-up. 949 
 950 
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Immunohistochemistry  952 
  Sections of 5 μm thickness were prepared from FFPE blocks, de-paraffinized 953 
and rehydrated by standard protocols. Depending on the antibodies used, antigen 954 
retrieval was performed either at pH 6 in a pressure cooker (Menapath Access 955 
Retrieval Unit, Menarini Diagnostics) or at pH 9 in a microwave. Sections were 956 
incubated in blocking buffer (1% BSA in PBS-T) for 1 hour followed by incubation 957 
with primary antibodies in blocking buffer for 2 hours, all at room temperature. 958 
Primary antibodies used were: mouse anti-ARPC3 (Millipore, MABT95; dilution 959 
1:2500), mouse anti-human CD31 (Dako, M0823; dilution 1:30), rabbit anti-mouse 960 
CD31 (Dianova, DIA310; dilution 1:75), rabbit anti-collagen-3 (Abcam, ab7778; 961 
dilution 1:200), mouse anti-cytokeratin-19 (Dako, M0888; dilution 1:100), mouse anti-962 
cytokeratin-20 (Dako, M7019; dilution 1:50), mouse anti-estrogen receptor alpha 963 
(ER) (Dako, M3643, dilution 1:80), mouse anti-hepatocyte specific antigen (Santa 964 
Cruz Biotechnology, sc-58693; dilution 1:400), mouse anti-pan-cytokeratin (Dako, 965 
M3515, dilution 1:75), rabbit anti-pan-cytokeratin (Dako, Z0622; dilution 1:400), 966 
mouse anti-Ki67 (Dako, M7240; dilution 1:300), mouse anti-progesterone receptor 967 
(PgR) (Dako, M3643; dilution 1:200) and rabbit anti-αSMA (Abcam, ab5694; dilution 968 
1:500). Antibody validation is provided on the manufacturers’ websites. For 969 
immunofluorescence, primary antibodies were detected with Alexa-488 or Alexa-555 970 
fluorescently-conjugated secondary antibodies (Invitrogen) diluted in blocking buffer 971 
supplemented with DAPI for 30 mins at room temperature, followed by mounting 972 
under glass coverslips in MOWIOL mountant supplemented with anti-fade (0.1% w/v 973 
1,4-diazabicyclo[2.2.2]octane) (Sigma). For DAB and TMB staining, primary 974 
antibodies were detected with Envision Flex system (K8002, Dako), followed by a 975 
light counterstain with hematoxylin before mounting under glass coverslips in DPEX 976 
mountant. For HER2 we used the HercepTest kit (SK001, Dako). Images were 977 
captured using a confocal laser-scanning microscope (Leica) or a light microscope 978 
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(Olympus), as appropriate.  979 
 980 
Scoring subtypes of breast cancer  981 
Cases of breast cancer liver metastasis were characterized for intrinsic 982 
molecular subtype as per published guidelines55. In brief, FFPE sections were 983 
stained for ER, PgR, HER2 or Ki67 and scored by a pathologist. For both ER and 984 
PgR, positive staining in ≥1% of tumor cell nuclei was required in order for the case 985 
to be considered receptor positive56. For HER2, the following system was utilized:  0 986 
or 1+ (HER2 negative), 2+ (HER2 borderline), or 3+ (HER2 positive)57. HER2 987 
borderline cases underwent additional testing using HER2 CISH pharmDx kit 988 
(SK109, Dako) to test for HER2 amplification. The presence of HER2 amplification 989 
was considered to indicate that the case was HER2 positive. Cases were deemed 990 
Ki67 ‘low’ if <14% of nuclei were Ki67 positive, otherwise they were considered to be 991 
Ki67 ‘high.’ The results of the ER, PgR, HER2 and Ki67 analysis were then used to 992 
assign each case to an intrinsic molecular subtype according to the criteria 993 
recommended by Goldhirsch et al 55 as detailed in Supplementary Table 13. 994 
 995 
Cell culture  996 
Luciferase-tagged HT29 cells (HT-29-luc2 from Caliper Life Sciences) were 997 
authenticated by STR typing and regularly tested for mycoplasma and shown to be 998 
contamination free. They were cultured in DMEM supplemented with 10% FCS, L-999 
glutamine and penicillin/streptomycin at 37°C in an atmosphere of 5% CO2.  1000 
 1001 
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shRNA knockdown  1003 
 HT29 cells were stably transduced with shRNA oligonucleotides using 1004 
lentiviral particles. We utilized three different shRNA oligonucleotides designed to 1005 
target ARPC3 (shARPC3-1, shARPC3-1, shARPC3-1) and a control oligonucleotide 1006 
with a validated non-targeting sequence (control shRNA) as follows:  1007 
 1008 
shARPC3-1 (5’CACCCGCTTAATAAGAATAAGTACGAATACTTATTCTTATTAAGCG3’)  1009 
shARPC3-2 (5’CACCGAAATGTATACGCTGGGAATCCGAAGATTCCCAGCGTATACATTTC3’)  1010 
shARPC3-3 (5’CACCGCCAAGGTGAGAAAGAAATGTCGAAACATTTCTTTCTCACCTTGGC3’) 1011 
control shRNA (5’CACCTAAGGCTATGAAGAGATACCG AAGTATCTCTTCATAGCCTTA3’) 1012 
  1013 
Oligonucleotides were ligated into the pENTR/U6 Gateway system entry vector 1014 
(Invitrogen) according to the manufacturer's instructions. Oligonucleotide sequences 1015 
were verified by sequencing and then transferred, together with the U6 promoter, into 1016 
the Gateway-modified pSEW lentiviral vector (this vector also contains the EGFP 1017 
gene under the control of an independent SFFV promoter). Viral supernatants were 1018 
generated by lipofectamine-2000 co-transfection of this expression vector and two 1019 
packaging vectors (psPAX2 and pMD2.G) into HEK293T cells. Viral supernatants 1020 
were collected and stored at -80°C until use. Adherent HT29 cells were infected with 1021 
viral supernatant for 24 hours. Following this, the infecting medium was aspirated 1022 
and replaced by DMEM complete. At 3–5 days after infection, HT29 cells were 1023 
trypsinized and sorted for GFP expression by flow cytometry on a FACS ARIA 1024 
instrument (BD Biosciences).  1025 
 1026 
  1027 
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Western blotting 1028 
Western blotting was performed as described58. In brief, cell lysates were 1029 
separated on 10% SDS-PAGE gels at 150 V for 1 hour.  Transfer to nitrocellulose 1030 
membranes was performed at 100 V for 1 hour. Membranes were blocked using 1031 
blocking buffer (TBS-T supplemented with 5% milk) and then probed with anti-1032 
ARPC3 antibodies (Santa Cruz Biotechnology, sc-136020; dilution 1:200) or anti-1033 
HSC70 antibodies (Santa Cruz Biotechnology, sc-7298; dilution 1:20,000). After 1034 
incubation with HRP-conjugated secondary antibodies in blocking buffer, membranes 1035 
were incubated with chemiluminescence substrate and exposed to films. 1036 
Densitometry was performed using ImageJ software on three independent western 1037 
blots. Expression levels of ARPC3 were normalized to the expression level of HSC-1038 
70. Antibody validation is provided on the manufacturer’s website.   1039 
 1040 
Cell motility assay 1041 
Cells were plated at a density of 50,000 cells per well in a 6-well plate. After 1042 
24 hours, the media was refreshed and the plates were transferred to the stage of an 1043 
inverted Leica IX-70 time-lapse microscope at 37°C in an atmosphere containing 5% 1044 
CO2. Images were captured through a 20X phase contrast objective every 30 1045 
minutes for 48 hours. To measure cell migration, random cells were tracked in time-1046 
lapse videos for 30 hours using the manual tracking plugin in ImageJ. For the 1047 
purposes of quantification, 30 cells from each experimental group were analyzed 1048 
from across two independent experiments. Results were expressed in terms of cell 1049 
velocity (μm per minute). 1050 
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Cell proliferation assay  1053 
To assess the proliferation kinetics of cells, 2000 HT29 cells were seeded (in 1054 
quadruplicate wells) on to four different 96-well plates (plates 1 to 4). Cell viability 1055 
was measured from plates 1, 2, 3 and 4 at 24, 48, 72 and 96 hours, respectively, 1056 
using the CellTitre-Glo reagent (Promega) according to the manufacturer’s 1057 
instructions. The quantity of viable cells was expressed relative to the signal at 24 1058 
hours from three independent experiments. 1059 
 1060 
Preclinical model of advanced liver metastasis 1061 
The Institute of Cancer Research Animal Ethics Committee granted approval 1062 
for animal work. Procedures were performed in accordance with United Kingdom 1063 
Home Office regulations. We used female CB17 SCID mice (CB17/lcr-1064 
Prkdcscid/lcrlcoCrl) at 12–16 weeks of age (obtained from Charles River UK). Parental 1065 
HT29 cells, or HT29 cells stably transduced with shRNA constructs, were 1066 
resuspended in growth factor-reduced Matrigel (Invitrogen) at a concentration of 1067 
1x107 cells per ml. Cells were introduced into the liver by laparotomy performed 1068 
under general anesthesia (inhaled isofluorane). A midline incision was made through 1069 
the peritoneum and the left main lobe of the liver was exteriorized. This lobe was 1070 
injected with 4x105 cells in a volume of 40 μL using a 29-gauge needle and then 1071 
returned to the peritoneal cavity, followed by closure of the wound. In order to assess 1072 
the effect of ARPC3 knockdown on the HGP (Fig. 6e) mice were culled 21 days post-1073 
injection of cancer cells. The tumor-bearing liver lobe was harvested, fixed in formalin 1074 
and embedded in paraffin. 1075 
For experiments where treatment was administered (Fig. 6f–h and 1076 
Supplementary Fig. 15), we waited for 10 days post- injection to allow for tumor 1077 
establishment. At 10 days, mice were injected subcutaneously with 75 mg per kg D-1078 
luciferin (Caliper Life Sciences), anesthetized with isofluorane and then imaged in an 1079 
Lumina II™ IVIS (In Vivo Imaging System) instrument (Caliper Life Sciences).  1080 
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Quantification of liver bioluminescence was performed using Living Image™ software 1081 
(Caliper Life Sciences) according to manufacturer’s instructions. The 1082 
bioluminescence measurement was used to ensure that subjects of equivalent tumor 1083 
burden were allocated to each experimental group.  1084 
Capecitabine powder (LC Laboratories) was dissolved in vehicle for oral 1085 
administration (40 mM citrate buffer pH 6, 5% gum Arabic). B20-4.1.1 (Genentech), 1086 
an antibody that blocks both mouse and human VEGF-A28, was formulated in sterile 1087 
PBS for intraperitoneal administration. One cycle of therapy consisted of the 1088 
following: mice received 500 mg per kg capecitabine or vehicle by oral gavage every 1089 
day for 5 days, followed 2 days treatment break, with intraperitoneal injection of 2.5 1090 
mg per kg B20-4.1.1 or vehicle on the first and fifth day of the cycle. In mice that 1091 
received capecitabine alone, the same protocol was followed but without the 1092 
administration of B20-4.1.1. Mice were administered two cycles of therapy and then 1093 
culled at 24 days post-injection of cancer cells. The tumor-bearing liver lobe was 1094 
harvested, fixed in formalin and embedded in paraffin. 1095 
For quantification of tumor burden, H&E-stained sections were prepared. 1096 
Sections were digitally scanned (Nanozoomer, Hamamatsu) and imported into NDPI 1097 
viewer software (Hamamatsu). The marquee tool was used freehand to create 1098 
regions of interest (ROIs) around areas of tumor in the section and tumor burden 1099 
measurement was calculated in terms of area in mm2. For quantification of vessel 1100 
density, sections were co-stained for CD31 (detected with TMB) and CK20 (detected 1101 
with DAB). Tumor vessels were manually counted and expressed in terms of vessels 1102 
per mm2 of tumor area. H&E-stained sections were scored for HGP according to the 1103 
same criteria used for human samples of liver metastasis. The scoring of tumor 1104 
burden, vessel density and HGPs was performed in a blinded fashion. The number of 1105 
mice per group was selected based on prior experience regarding the minimum 1106 
number of animals necessary to detect a statistically significant difference between 1107 
experimental groups. No randomization method was used.  1108 
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 1109 
ARPC3 staining  1110 
 HT29 cells stably transfected with the control shRNA or shARPC3-3 were 1111 
grown to confluency, washed in PBS, harvested by trypsinization and then pelleted 1112 
by centrifugation. Pelleted cells (approximately 1x107 cells per pellet) were then 1113 
resuspended in formalin and fixed for 15 minutes followed by pelleting again and 1114 
embedding in paraffin. Tissue sections were prepared and then stained using anti-1115 
ARPC3 antibody (Millipore, MABT95; dilution 1:2500) as described above (see 1116 
Immunohistochemistry) with antigen retrieval performed in pH 6 citrate buffer with 1117 
heating in a microwave for 18 minutes.  1118 
 The same staining protocol was used to stain for ARPC3 in FFPE tissue 1119 
sections of human liver metastasis specimens. Positive staining for ARPC3 was 1120 
observed in cancer cells and in some stromal cell types (including immune cells and 1121 
Kuppfer cells), but only cancer cell staining was scored. The scoring of ARPC3 1122 
staining intensity in cancer cells was performed semi-quantitatively by a pathologist. 1123 
For each case examined, the percentage of cancer cells having 1+ (weak), 2+ 1124 
(moderate) or 3+ (strong) staining intensity was scored. The result for each case was 1125 
expressed as an H-score as calculated by the formula: (% area of weak staining) + (2 1126 
x % area of moderate staining) + (3 x % area of strong staining). This generated a 1127 
score between 0 - 300 for each case. 1128 
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Statistical analysis 1131 
 The univariate analysis of clinical data reported in Figs. 1 and 2, in 1132 
Supplementary Figs. 3, 5, 6, 7 and 8, and in Supplementary Tables 2, 4, 9 and 10 1133 
was performed using the two-tailed χ2 test. A univariate and multivariate analysis on 1134 
181 lesions from 90 patients was performed to determine clinical characteristics 1135 
significantly associated with a good pathological response. Given that some lesions 1136 
came from the same patient, a generalized estimating equation (GEE) approach was 1137 
used to account for the within-patient covariance (exchangeable working correlation 1138 
structure was used to specify the correlation among lesions clustered within the 1139 
same patient). A total of 12 different clinical variables were included in the univariate 1140 
analysis. Only 5 variables which met a pre-defined threshold for association with 1141 
pathological response in the univariate GEE analysis (P-value <0.25) were then 1142 
included in the subsequent multivariate GEE analysis. The results of the analysis are 1143 
reported in Supplementary Table 5. 1144 
For the overall survival data, the Log-Rank test was used to determine the 1145 
statistical signficance and Cox proportional hazards regression was used to 1146 
determine hazard ratios (Fig. 4b–e). A univariate and multivariate analysis to 1147 
determine clinical characteristics associated with overall survival was performed 1148 
using the Cox proportional hazards regression model. A total of 12 different clinical 1149 
variables were included in the univariate analysis. Only 2 variables which met a pre-1150 
defined threshold for association with overall survival in the univariate analysis (P-1151 
value <0.25) were then included in the subsequent multivariate analysis. The results 1152 
of the analysis are reported in Supplementary Table 8. The proportional hazards 1153 
assumption for the Cox regression models was tested based on weighted 1154 
Schoenfeld residuals59: for the overall survival analyses (Fig. 4b–e) the P-values 1155 
calculated ranged from 0.09 to 0.69, for the univariate analyses the P-values 1156 
calculated ranged from 0.08 to 0.99 (depending on the variable), whilst the global P-1157 
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value calculated for the multivariate analysis was 0.85, indicating that the 1158 
proportional hazards ratio assumption was not rejected in any instance. 1159 
 Where appropriate, the Kolmogorov-Smirnov normality test was used to 1160 
determine the normality of the data and the F-test equality of variances test was used 1161 
to determine whether the variance between groups was similar. For normally 1162 
distributed data, we used two-tailed unpaired Student’s t-test (with Welch’s correction 1163 
applied if the variance between groups was not similar) to compare experimental 1164 
groups (Fig. 6g,h and Supplementary Figs. 11h and 15b,c). For non-normally 1165 
distributed data we used Kruskal-Wallis test (Fig. 4a) or Mann-Whitney U-test (Fig. 1166 
6d-f and Supplementary Fig. 15a) to compare experimental groups. For data where 1167 
the sample number was too small (n = 3 independent experiments) to determine 1168 
normality, but where the variance between groups was similar, we used two-tailed 1169 
unpaired Student’s t-test to compare experimental groups (Fig. 6c and 1170 
Supplementary Fig. 13). Intra- and inter-observer agreement for scoring the HGPs 1171 
was analyzed using Pearson’s correlation co-efficient and Bland-Altman plots 1172 
(Supplementary Fig. 17). For all statistical analyses, P-values below 0.05 were 1173 
considered statistically significant. 1174 
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Supplementary Figure 1 Morphology of the three histopathological growth 
patterns (HGPs) of colorectal cancer liver metastases  
a–h. Diagrams and H&E–stainings illustrate the morphology of normal liver or the 
morphology of the tumor–normal liver interface in human CRC liver metastases with a 
desmoplastic, pushing or replacement HGP.   
i–t. To confirm the distinct tumor–stroma interaction that occurs in each HGP, we 
performed additional staining for hepatocyte specific antigen (HSA), collagen–3 (col–
3) and alpha smooth muscle actin (αSMA). In normal liver, HSA labeled hepatocytes 
(i), col–3 labeled sinusoidal blood vessels (m), whilst αSMA labeled neither 
hepatocytes nor sinusoidal blood vessels (q). In the desmoplastic HGP, a 
desmoplastic stroma physically separates cancer cells from normal liver (b,f). Co–
staining for pan–cytokeratin (CK) to detect cancer cells and HSA to detect 
hepatocytes confirmed physical separation of cancer cells and normal liver (j), whilst 
co–staining for pan–cytokeratin and col–3, or pan–cytokeratin and αSMA, confirmed 
the presence of a desmoplastic stroma abundant in collagen (n) and αSMA–positive 
fibroblasts (r), respectively. In the pushing HGP, cancer cells and normal liver are in 
close contact with no intervening desmoplastic stroma (c,g) which was confirmed by 
co–staining for CK and HSA (k) or CK and αSMA (s). Another feature of the pushing 
HGP, physical compression of sinusoidal vessels in adjacent normal liver tissue, was 
confirmed by co–staining for pan–cytokeratin and col–3 (o). In the replacement HGP, 
cancer cells infiltrate the liver parenchyma and replace hepatocytes without disturbing 
the vascular architecture of the liver; no desmoplastic stroma is observed (d,h). 
Supporting this, co–staining for CK and HSA confirmed the invasion of cancer cells 
into liver parenchyma (l). Co–staining for CK and col–3 showed that the vascular 
architecture of the adjacent liver was preserved at the tumor–liver interface (p). Lack 
of αSMA staining confirmed the absence of a desmoplastic stroma (t). Asterisk, 
cancer cells. DS, desmoplastic stroma. Lv, normal liver. Scale bars, 50 µM. 
CRC liver resections performed after preoperative 
treatment with bev–chemo at RM during the
period 2006 – 2012:  
n = 101 lesions from 47 patients
Recovery of FFPE tissue blocks 
Tissue not available for assessment:
n = 16 lesions
FFPE tissue blocks assessed by pathologists 
for presence of tumour tissue   Liver lesions were excluded from further 
histopathological analysis for the following 
reasons: 
Tissue block(s) did not contain any tumour 
tissue (n = 12 lesions)
Tissue was too poor quality for reliable 
assessment (n = 1 lesion)
Analysis of pathological response by pathology 
team:
n = 67 lesions from 37 patients
Liver lesions were excluded from assessment 
of histopathogical growth pattern because a 
complete pathological response was scored: 
n = 8 lesions 
Analysis of histopathogical growth pattern by 
pathology team:
n = 59 lesions from 33 patients
Analysis of morphological response criteria from 
CT scans:
n = 52 lesions from 31 patients
Liver lesions were excluded from morphological 
response criteria assessment because CT scans
were of insufficient quality or because the pre– 
and post–treatment scans were performed at 
different sites:
n = 7 lesions  
Liver lesions that were absent from baseline 
pre-treatment scans, but presented after the 
initiation of bev–chemo treatment:
n = 5 lesions from 1 patient 
Supplementary Figure 2
Supplementary Figure 2 Consort diagram for RM cohort 
Consort diagram to illustrate how cases of CRC liver metastases from patients treated preoperatively 
with bev–chemo at RM were selected for inclusion in the study or excluded.
Supplementary Table 1 Characteristics of bev–chemo treated CRC patients in the 
RM cohort  
 
Characteristics of 33 patients (n = 59 lesions) treated preoperatively with bev-chemo prior to 
liver resection at RM. 
 
Demographics  
Gender, number of patients (%) 
 Male 
 Female 
 
21 (63.6) 
12 (36.4) 
Age, median (range)  63 (29 – 79) 
Primary tumor  
Site of primary tumor, number of patients (%) 
 Rectum 
 Recto–sigmoid 
 Colon 
 
7 (21.2) 
14 (42.4) 
12 (36.4) 
Lymph node status, number of patients (%) 
 Positive 
 Negative 
 
26 (78.8) 
7 (21.2) 
Histological grade, number of patients (%) 
 High grade 
 Low grade 
 
4 (12.1) 
29 (87.9) 
Adjuvant therapy, number of patients (%) 
 Yes 
 No 
 
10 (30.3) 
23 (69.7) 
Liver metastasis  
No. of liver lesions at presentation, number of patients (%) 
 Solitary lesion 
 Multiple lesions 
 
11 (33.3) 
22 (66.7) 
No. of liver lesions utilised for histopathological analysis  
per patient, number of patients (%) 
 1 lesion 
 2 lesions 
 3 lesions 
 4 lesions 
 
 
17 (51.5) 
10 (30.3) 
2 (6.1) 
4 (12.1) 
Baseline lesion size, median (range) 21 mm (5 – 110) 
Preoperative therapy administered, number of patients (%) 
 CAPOX + bevacizumab 
 FOLFOX + bevacizumab 
 FOLFIRI + bevacizumab 
 
21 (63.6) 
5 (15.2) 
7 (21.2) 
Cycles of preoperative therapy, median (range) 6 (4 – 12) 
Interval between last bevacizumab dose and resection, median (range) 76 days (41 – 362) 
 
Footnote: CAPOX, capecitabine and oxaliplatin; FOLFOX, infusional 5–fluorouracil and 
oxaliplatin; FOLFIRI, infusional 5–fluorouracil and irinotecan. 
  
Supplementary Figure 3
Supplementary Figure 3 Correlation between HGP and pathological response in an analysis restricted 
to one lesion per patient (RM cohort)
Data are presented from the same series of 33 patients as depicted in Figure 1b, but for this analysis only one 
lesion per patient was used. The graph shows the % HGP (replacement, desmoplastic, pushing) scored in the 
largest lesion from each patient. Lesions scored as >75%, 50-75% or 25-49% viable were considered to be 
poor responders, whilst lesions scored as <25% viable were considered good responders. Lesions with a 
substantial (≥50%) replacement HGP were significantly enriched in the poor responder group when compared 
with good responders (P < 0.001), whilst lesions with a substantial (≥50%) desmoplastic HGP were 
significantly enriched in the good responder group when compared with poor responders (P < 0.001). The χ2 
test was used to determine statistical significance (see 2x2 contingency tables).
Individual CRC liver metastases (RM cohort)
0
20
40
60
80
100
>75% viable 50-75% viable 25-49% viable <25% viable
Poor pathological 
response
Good pathological 
response
H
G
P 
(%
)
Replacement (R)
Desmoplastic (D)
Pushing (P)
Response
Poor Good
  <50% R
  Total
  Total
16 (100%) 0 (0%)
6 (35.3%) 11 (64.7%) 
16 (100%)
17 (100%)
22 (66.7%) 11 (33.3%) 33 (100%)
  ≥50% R
No. of 
lesions
Response
Poor Good
  <50% D
  Total
  Total
4 (26.7%) 11 (73.3%)
18 (100%) 0 (0%) 
15 (100%)
18 (100%)
22 (66.7%) 11 (33.3%) 33 (100%)
P < 0.001
  ≥50% D
No. of 
lesions
P < 0.001
Supplementary Table 2 Univariate analysis of clinical characteristics associated 
with pathological response in RM patients treated preoperatively with bev–chemo 
 
Analysis was performed using data for 59 lesions from 33 patients treated preoperatively with 
bev-chemo prior to liver resection (RM cohort). The χ2 test was used to determine statistical 
significance. 
 
Variables Total number 
of lesions 
Lesions with <25% 
viable tumor, no. (%) 
P–value  
Demographics    
Gender  
 Male 
 Female 
 
34 
25 
 
12 (35.3) 
10 (40) 
 
0.712 
Age  
 <60 years 
 ≥60 years 
 
17 
42 
 
6 (35.3) 
16 (38.1) 
 
0.840 
Primary tumor     
Site of primary tumor 
 Rectum 
 Recto–sigmoid 
 Colon 
 
13 
24 
22 
 
4 (30.8) 
8 (33.3) 
10 (45.5) 
 
0.599 
 
Lymph node status 
 Positive 
 Negative 
 
48 
11 
 
19 (39.6) 
3 (27.3) 
 
0.446 
Histological grade 
 High grade 
 Low grade 
 
8 
51 
 
5 (62.5) 
17 (33.3) 
 
0.113 
Adjuvant therapy 
 Yes 
 No 
 
18 
41 
 
4 (22.2) 
18 (43.9) 
 
0.113 
Liver metastasis    
No. of liver lesions at presentation 
 Solitary 
 Multiple 
 
11 
48 
 
5 (45.5) 
17 (35.4) 
 
0.535 
Baseline lesion size 
 <20 mm 
 ≥20 mm 
 
24 
35 
 
11 (45.8) 
11 (31.4) 
 
0.261 
Preoperative therapy administered 
 CAPOX + bevacizumab 
 FOLFOX + bevacizumab 
 FOLFIRI + bevacizumab 
 
37 
9 
13 
 
16 (42.1) 
2 (22.2) 
4 (30.8) 
 
0.475 
Cycles of preoperative therapy 
 ≤6 cycles 
 >6 cycles 
 
44 
15 
 
16 (36.4) 
6 (40.0) 
 
0.801 
Interval between last bevacizumab 
dose and resection 
 <70 days 
 ≥70 days 
 
 
24 
35 
 
 
10 (41.7) 
12 (34.3) 
 
 
0.565 
 
Table continues overleaf 
 
 
  
Supplementary Table 2 continued 
 
 
Footnote: CAPOX, capecitabine and oxaliplatin; FOLFOX, infusional 5–fluorouracil and 
oxaliplatin; FOLFIRI, infusional 5–fluorouracil and irinotecan; N/A, data not available. 
 
  
Variables 
 
Total number 
of lesions 
Lesions with <25% 
viable tumor, no (%) 
P–value  
Response measures    
Change in lesion size by RECIST  
 PR 
 SD or PD 
 
34 
25 
 
15 (44.1) 
7 (28.0) 
 
  0.206 
Morphological response on CT 
 Yes (OR or PR) 
 No (AR)  
 
19 
33 
 
11 (57.9) 
10 (30.3) 
 
0.051 
Histopathological growth pattern    
Replacement HGP 
 <25% 
 ≥25% 
 
28 
31 
 
20 (71.4) 
2 (6.5) 
 
<0.001 
Replacement HGP 
 <50% 
 ≥50% 
 
32 
27 
 
21 (65.6) 
1 (3.7) 
 
<0.001 
Desmoplastic HGP 
 <25% 
 ≥25% 
 
25 
34 
 
0 (0) 
22 (64.7) 
 
<0.001 
Desmoplastic HGP 
 <50% 
 ≥50% 
 
28 
31 
 
1 (3.6) 
21 (67.7) 
 
<0.001 
CRC liver resections performed after preoperative 
treatment with bev-chemo at MUHC during the 
period 2008-2014: 
n = 191 lesions from 65 patients
Recovery of FFPE tissue blocks 
Tissue not available for assessment:
n = 1 lesion
FFPE tissue blocks assessed by pathologists 
for presence of tumour tissue   Liver lesions were excluded from further 
histopathological analysis for the
following reasons:
Tissue block(s) did not contain any tumour 
tissue: n = 15 lesions
Tissue was too poor quality for reliable 
assessment: n = 3 lesions 
Analysis of pathological response by pathology 
team:
n = 137 lesions from 61 patients 
Liver lesions were excluded from assessment 
of histopathogical growth pattern because a 
complete pathological response was scored: 
n = 9 lesions
Analysis of histopathogical growth pattern by 
pathology team:
n = 128 lesions from 59 patients 
Liver lesions that were absent from baseline 
pre-treatment scans, but presented after the 
initiation of bev-chemo treatment (new CRCLMs): 
n = 35 lesions from 13 patients
Supplementary Figure 4
Supplementary Figure 4 Consort diagram for MUHC cohort 
Consort diagram to illustrate how cases of CRC liver metastases from patients treated preoperatively 
with bev-chemo at MUHC were selected for inclusion in the study or excluded.
Supplementary Table 3 Characteristics of bev–chemo treated CRC patients in the 
MUHC cohort 
 
Characteristics of 59 patients (n = 128 lesions) treated preoperatively with bev-chemo at MUHC. 
 
Demographics  
Gender, number of patients (%) 
 Male 
 Female 
 
35 (59.3) 
24 (40.7) 
Age, median (range)  63 (30 – 85) 
Primary tumor  
Site of primary tumor, number of patients (%) 
 Rectum 
 Recto–sigmoid 
 Colon 
 
11 (18.6) 
9 (15.3) 
39 (66.1) 
Lymph node status, number of patients (%) 
 Positive 
 Negative 
N/A 
 
32 (54.2) 
8 (13.6) 
19 (32.2) 
Histological grade, number of patients (%) 
 High grade 
 Low grade 
N/A 
 
4 (6.8) 
36 (61.0) 
19 (32.2) 
Adjuvant therapy, number of patients (%) 
 Yes 
 No 
N/A 
 
12 (20.3) 
46 (78.0) 
1 (1.7) 
Liver metastasis  
No. of liver lesions at presentation, number of patients (%) 
 Solitary lesion 
 Multiple lesions 
 
18 (30.5) 
41 (69.5) 
No. of liver lesions utilised for histopathological analysis  
per patient, number of patients (%) 
 1 lesion 
 2 lesions 
 3 lesions 
 4 lesions 
 5 lesions  
 6 lesions 
 8 lesions 
 12 lesions 
 
 
29 (49.2) 
15 (25.4) 
7 (11.8) 
3 (5.1) 
2 (3.4) 
1 (1.7) 
1 (1.7) 
1 (1.7) 
Baseline lesion size, median (range) 26 (5 – 190)* 
Preoperative therapy administered, number of patients (%) 
 FOLFOX + bevacizumab 
 FOLFIRI + bevacizumab 
 
47 (79.7) 
12 (20.3) 
Cycles of preoperative therapy, median (range) 6 (2 – 13) 
Interval between last bevacizumab dose and resection,  
median (range) 
 
64 (23 – 237) 
 
Footnote: FOLFOX, infusional 5–fluorouracil and oxaliplatin; FOLFIRI, infusional 5–
fluorouracil and irinotecan; N/A, data not available. *Information on baseline lesion size was 
available for 113 out of 128 lesions.   
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Supplementary Figure 5
Supplementary Figure 5 Correlation between HGP and pathological response in an analysis restricted 
to one lesion per patient (MUHC cohort)
Data are presented from the same series of 59 patients as depicted in Figure 1f, but for this analysis only one 
lesion per patient was used. The graph shows the % HGP (replacement, desmoplastic, pushing) scored in the 
largest lesion from each patient. Lesions scored as >75%, 50-75% or 25-49% viable were considered to be 
poor responders, whilst lesions scored as <25% viable were considered good responders. Lesions with a 
substantial (≥50%) replacement HGP were significantly enriched in the poor responder group when compared 
with good responders (P < 0.001), whilst lesions with a substantial (≥50%) desmoplastic HGP were 
significantly enriched in the good responder group when compared with poor responders (P < 0.001). The χ2 
test was used to determine statistical significance (see 2x2 contingency tables).
Supplementary Table 4 Univariate analysis of clinical characteristics associated 
with pathological response in MUHC patients treated preoperatively with bev–
chemo 
 
Analysis was performed using data for 128 lesions from 59 patients treated preoperatively with 
bev-chemo prior to liver resection (MUHC cohort). The χ2 test was used to determine statistical 
significance. 
 
Variables Total number 
of lesions 
Lesions with <25% 
viable tumor, no. (%) 
P–value  
Demographic    
Gender  
 Male 
 Female 
 
88 
40 
 
29 (32.9) 
17 (42.5) 
 
0.297 
Age  
 <60 years 
 ≥60 years 
 
53 
75 
 
18 (34.0) 
28 (37.3) 
 
0.695 
Primary tumor     
Site of primary tumor 
 Rectum 
 Recto–sigmoid 
 Colon 
 
21 
14 
93 
 
5 (23.8) 
8 (57.1) 
33 (35.5) 
 
0.022 
 
Lymph node status 
 Positive 
 Negative 
 
66 
11 
 
20 (30.3) 
7 (63.6) 
 
0.032 
Histological grade 
 High grade 
 Low grade 
 
6 
72 
 
1 (16.7) 
28 (38.9) 
 
0.279 
Adjuvant therapy 
 Yes 
 No 
 
24 
103 
 
6 (25) 
40 (38.8) 
 
0.204 
Liver metastasis    
No. of liver lesions at presentation 
 Solitary 
 Multiple 
 
18 
110 
 
7 (38.9) 
39 (35.4) 
 
0.778 
 
Baseline lesion size 
 <20 mm 
 ≥20 mm 
 
40 
73 
 
13 (32.5) 
29 (39.7) 
 
0.447 
Preoperative therapy administered 
 FOLFOX + bevacizumab 
 FOLFIRI + bevacizumab 
 
108 
20 
 
42 (38.9) 
4 (20.0) 
 
0.048 
Cycles of preoperative therapy 
 ≤6 cycles 
 >6 cycles 
 
86 
42 
 
37 (43) 
9 (21.4) 
 
0.017 
Interval between last bevacizumab 
dose and resection 
 <70 days 
 ≥70 days 
 
 
58 
70 
 
 
22 (37.9) 
24 (34.3) 
 
 
0.669 
 
Table continues overleaf 
 
 
  
Supplementary Table 4 continued  
 
 
Footnote: FOLFOX, infusional 5–fluorouracil and oxaliplatin; FOLFIRI, infusional 5–fluorouracil 
and irinotecan; N/A, data not available. 
 
  
Variables 
 
Total number 
of lesions 
Lesions with <25% 
viable tumor, no (%) 
P–value  
Response measures    
Change in lesion size by RECIST  
 PR 
 SD or PD 
 
44 
69 
 
22 (50) 
20 (29) 
 
0.024 
Histopathological growth pattern    
Replacement HGP 
 <25% 
 ≥25% 
 
60 
68 
 
34 (56.7) 
23 (17.7) 
 
<0.001 
Replacement HGP 
 <50% 
 ≥50% 
 
70 
58 
 
40 (57.1) 
6 (10.3) 
 
<0.001 
Desmoplastic  HGP 
 <25% 
 ≥25% 
 
48 
80 
 
2 (4.2) 
44 (55) 
 
<0.001 
Desmoplastic  HGP 
 <50% 
 ≥50% 
 
62 
66 
 
6 (9.7) 
40 (60.6) 
 
<0.001 
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Supplementary Figure 6 The HGPs correlate with pathological response in patients presenting with 
a single lesion only
The graph shows the HGPs and pathological response in 29 patients that presented with a single lesion only. 
Graph shows the % HGP (replacement, desmoplastic, pushing) scored in each lesion from each patient. 
Lesions scored as >75%, 50-75% or 25-49% viable were considered to be poor responders, whilst lesions 
scored as <25% viable were considered good responders. Lesions with a substantial (≥50%) replacement 
HGP were significantly enriched in the poor responder group when compared with good responders 
(P=0.0264). Lesions with a substantial (≥50%) desmoplastic HGP were significantly enriched in the good 
responder group when compared with poor responders (P=0.0128). The χ2 test was used to determine 
statistical significance (see 2x2 contingency table).
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Supplementary Table 5 Univariate and multivariate analysis of clinical characteristics 
associated with pathological response in lesions treated preoperatively with bev–chemo 
 
Data from patients that received preoperative therapy with bev–chemo were used to determine clinical 
variables associated with a good pathological response (lesions were pooled from RM and MUHC). Only 
lesions with ≥50% replacement HGP (85 lesions) or ≥50% desmoplastic HGP (96 lesions) were included. 
Lesions with ≥50% pushing HGP were excluded (6 lesions). The final analysis was therefore performed 
on 181 lesions from 90 patients. Both the univariate analysis and the multivariate analysis were 
performed using a generalized estimating equation. Only 5 variables that met a pre–defined threshold of 
P<0.25 in the univariate analysis were included in the subsequent multivariate analysis. 
 
 
 
 
Univariate analysis Multivariate analysis 
 OR (95% CI) P–value OR (95% CI) P–value 
Demographics     
Gender   
   Male 
   Female 
 
0.83 (0.69 – 1.00) 
1.21 (1.00 – 1.45) 
 
0.0507 
 
0.80 (0.32 – 2.00) 
1.25 (0.50 – 3.16) 
 
0.6304 
Age  
<60 years  
≥60 years 
 
1.03 (0.85 – 1.24) 
0.97 (0.81 – 1.18) 
 
0.7629 
– – 
Primary tumour     
Site of primary tumor  
   Rectum 
   Colon / recto–sigmoid 
 
0.91 (0.74 – 1.11) 
1.10 (0.90 – 1.35) 
 
0.3502 
 
– 
 
– 
Lymph node status  
   Positive  
   Negative  
 
0.68 (0.25 – 1.89) 
1.47 (0.53 – 4.06) 
 
0.4565 
 
– 
 
– 
Histological grade 
   High grade 
   Low grade   
 
1.16 (0.30 – 4.55) 
0.86 (0.22 – 3.35) 
 
0.8259 
 
– 
 
– 
Adjuvant therapy  
   Yes 
   No   
 
0.85 (0.70 – 1.03) 
1.17 (0.97 – 1.42) 
 
0.1087 
 
0.48 (0.17 – 1.41) 
2.07 (0.71 – 6.01) 
 
0.1834 
Liver metastasis     
Number of lesions at presentation  
   Solitary  
   Multiple 
 
1.07 (0.87 – 1.32) 
0.93 (0.76 – 1.15) 
 
0.5275 
 
– 
 
– 
Baseline lesion size 
   <20 mm 
   ≥20 mm 
 
0.99 (0.49 – 2.01) 
1.01 (0.50 – 2.04) 
 
0.9730 
 
– 
 
– 
Preoperative therapy 
administered 
   CAPOX + bev / FOLFOX + bev  
   FOLFIRI + bev 
 
 
2.09 (0.76 – 5.78) 
0.48 (0.17 – 1.32) 
 
 
0.1534 
 
 
1.14 (0.37 – 3.51) 
0.88 (0.29 – 2.70) 
 
 
0.8237 
Cycles of preoperative therapy  
   ≤6 cycles 
   >6 cycles 
 
2.03 (0.82 – 5.02) 
0.49 (0.20 – 1.22) 
 
0.1249 
 
1.74 (0.71 – 4.28) 
0.57 (0.23 – 1.41) 
 
0.2256 
Interval between last 
bevacizumab dose and resection 
   <70 days 
   ≥70 days 
 
 
1.41 (0.66 – 3.03) 
0.71 (0.33 – 1.52) 
 
 
0.3782 
 
 
– 
 
 
– 
HGP 
≥50% replacement  
   ≥50% desmoplastic  
 
0.07 (0.03 – 0.16) 
15.06 (6.32 – 35.87) 
 
<0.0001 
 
0.06 (0.03 – 0.15) 
15.92 (6.76 – 37.51) 
 
<0.0001 
 
Footnote: For every variable tested, we present the odds ratio in both directions e.g. male vs female 
(OR=0.83) and its reverse, female vs male (OR=1.21), etc.  
 
bev, bevacizumab; CAPOX, capecitabine and oxaliplatin; FOLFOX, infusional 5–fluorouracil and 
oxaliplatin; FOLFIRI, infusional 5–fluorouracil and irinotecan. 
Supplementary Figure 7 
Supplementary Figure 7 Correlation between HGP and morphological response in an analysis 
restricted to one lesion per patient (RM cohort)
Data are presented from the same series of 31 patients as depicted in Figure 2g, but for this analysis 
only one lesion per patient was used. The graph shows the % HGP (replacement, desmoplastic, 
pushing) scored in the largest lesion from each patient. Lesions scored as having an absent 
morphological response (AR) were considered to be poor responders, whilst those undergoing a 
partial (PR) or optimal (OR) morphological response were considered to be good responders. Lesions 
with ≥50% replacement HGP were significantly enriched in poor responders compared to good 
responders  (P = 0.0357). The χ2 test was used to determine statistical significance (see 2x2 
contingency table).
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Supplementary Figure 8 The HGPs do not correlate with response when using RECIST criteria as a 
response measure
Response to bev-chemo was scored using RECIST criteria in order to categorise individual lesions as: progressive 
disease (PD), stable disease (SD) or partial response (PR). Graph shows the % HGP scored in each individual 
lesion (replacement, desmoplastic, pushing) with lesions grouped according to response: PD, SD or PR (n = 59 liver 
metastases from 33 patients). Lesions scored as PD or SD were considered to be poor responders, whilst lesions 
scored as PR were considered to be good responders. Lesions with a substantial (≥50%) replacement HGP were 
not significantly enriched in the poor responder group when compared with good responders (P=0.440). The χ2 test 
was used to determine statistical significance (see 2x2 contingency table).
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Supplementary Figure 9 Staining for blood vessels in the different histopathological growth patterns
Resection specimens of CRCLMs corresponding to the three different HGPs were stained for cytokeratin 20 
(CK20) to identify cancer cells (brown) and CD31 to identify vessels (blue). a,b. Replacement HGP. Co-option of 
sinusoidal vessels by invading cancer cells is observed. c,d. Desmoplastic HGP. Co-option of sinusoidal vessels 
by cancer cells is physically precluded by the desmoplastic stroma (DS) that separates cancer cells from the 
normal liver (Lv). Dashed line indicates where the desmoplastic rim of the tumor meets the normal liver. e,f. Push-
ing HGP. Sinusoidal vessels that are present in the normal liver adjacent to the tumor are compressed, highly elon-
gated and run in parallel with the tumor-liver interface, a topology that physically precludes the co-option of these 
vessels by invading cancer cells. DS, desmoplastic stroma. Lv, normal liver. Scale bar, 50 μM.
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Supplementary Figure 10 Co-staining for blood vessels and hepatocytes in the different histopathological 
growth patterns
Resection specimens of CRCLMs were stained for HSA to identify hepatocytes (brown) and CD31 to identify 
vessels (blue). a. Normal liver, b. replacement HGP, c. desmoplastic HGP, and d. pushing HGP. Dashed line 
indicates the interface where the tumor meets the normal liver. Arrowheads indicate co-opted sinsuoidal vessels 
that are still associated with hepatocytes. DS, desmoplastic stroma. Lv, normal liver. Scale bar, 50 μM.
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Supplementary Table 6 Characteristics of MUHC patients that presented with new 
CRC liver metastases after bev–chemo treatment was initiated (new CRCLMs) 
 
 
Demographics  
Gender, number of patients (%) 
 Male 
 Female 
 
9 (69.2) 
4 (30.8) 
Age, median (range)  65 (46–78) 
Primary tumor  
Site of primary tumor, number of patients (%) 
 Rectum 
 Recto–sigmoid 
 Colon 
 
2 (15.4)  
3 (23.1) 
8 (61.5) 
Lymph node status, number of patients (%) 
 Positive 
 Negative 
N/A 
 
10 (76.9) 
0 
3 (23.1) 
Histological grade, number of patients (%) 
 High grade 
 Low grade  
 N/A 
 
2 (15.4) 
8 (61.5) 
3 (23.1) 
Adjuvant therapy, number of patients (%) 
 Yes 
 No 
 
4 (30.8) 
9 (69.2) 
Liver metastasis   
Quantity of liver lesions present when treatment started,  
number of patients (%) 
 No lesion* 
 Solitary lesion  
 Multiple lesions 
 
 
2 (15.4) 
2 (15.4) 
9 (69.2) 
Quantity of new liver lesions presenting after treatment started, 
number of patients (%)  
 Solitary lesion  
 Multiple lesions 
 
 
7 (53.8) 
6 (46.2) 
No. of liver lesions utilised for histopathological analysis  
per patient, number of patients (%) 
 1 lesion 
 2 lesions 
 3 lesions 
 5 lesions 
 14 lesions 
 
 
7 (53.8) 
3 (23.1) 
1(7.7) 
1 (7.7) 
1 (7.7) 
Preoperative therapy administered, number of patients (%)  
 FOLFOX + bevacizumab 
 FOLFIRI + bevacizumab 
 
9 (69.2) 
4 (30.8) 
Cycles of preoperative therapy, median (range) 6 (5 – 12)  
Interval between last bevacizumab dose and resection,  
median (range) 
 
67 days (43 – 126) 
 
Footnote: *Two patients were administered bev-chemo prior to detection of liver metastases: one patient 
was receiving adjuvant bev-chemo when liver disease was detected and a second patient was receiving 
bev-chemo for CRC lung metastasis when liver disease was detected. bev, bevacizumab; CAPOX, 
capecitabine and oxaliplatin; FOLFOX, infusional 5–fluorouracil and oxaliplatin; FOLFIRI, infusional 5–
fluorouracil and irinotecan. N/A, data not available. 
Supplementary Table 7 Characteristics of MUHC patients that received no 
preoperative therapy prior to resection of CRC liver metastases (untreated 
CRCLMs) 
 
 
Demographics  
Gender, number of patients (%) 
 Male 
 Female 
 
11 (57.9) 
8 (42.1) 
Age, median (range)  70 (33 – 80) 
Primary tumor  
Site of primary tumor, number of patients (%) 
 Rectum 
 Recto–sigmoid 
 Colon 
 
5 (26.3) 
1 (5.3) 
13 (68.4) 
Lymph node status, number of patients (%) 
 Positive 
 Negative 
N/A 
 
10 (52.6) 
5 (26.3) 
4 (21.1) 
Histological grade, number of patients (%) 
 High grade 
 Low grade 
N/A 
 
1 (5.3) 
10 (52.6) 
8 (42.1) 
Adjuvant therapy, number of patients (%) 
 Yes* 
 No (completely chemonaive) 
 
4 (21.1) 
15 (78.9) 
Baseline features of the liver metastases  
No. of liver lesions at presentation, number of patients (%) 
 Solitary lesion 
 Multiple lesions 
 
12 (63.2) 
7 (36.8)  
No. of liver lesions utilised for histopathological analysis  
per patient, number of patients (%) 
 1 lesion 
 2 lesions 
 4 lesions 
 6 lesions 
 
 
12 (61.1) 
5 (26.3) 
1 (5.3) 
1 (5.3) 
Baseline lesion size, median (range) 13.5 mm (4 – 77) 
 
Footnote: *patients were only included if the last dose of adjuvant therapy was administered ≥ 
365 days prior to diagnosis of liver metastasis (median interval between last dose of adjuvant 
therapy and diagnosis of liver metastasis in these 4 patients was 1161 days, range was 789 – 
1667 days). Adjuvant therapy consisted of chemotherapy only and no patients received 
adjuvant bevacizumab. N/A, data not available. 
 
 
 
 
 
 
 
Supplementary Table 8 Univariate and multivariate analysis of clinical characteristics 
associated with overall survival in patients treated preoperatively with bev–chemo 
 
Data from patients that received preoperative therapy with bev–chemo at MUHC were used to determine 
clinical variables associated with overall survival. Only patients in the predominant replacement subgroup 
(26 patients) or the predominant desmoplastic subgroup (35 patients) were included in the analysis. The 
predominant pushing subgroup (1 patient) was excluded from the analysis. The final analysis was 
therefore performed on 61 patients. Both the univariate analysis and the multivariate analysis were 
performed using Cox proportional hazards regression. Only 2 variables that met a pre–defined threshold 
of P<0.25 in the univariate analysis were included in the subsequent multivariate analysis. 
 
 
 
 
Univariate analysis Multivariate analysis 
 HR (95% CI) P–value HR (95% CI) P–value 
Demographics     
Gender   
   Male 
   Female 
 
1.14 (0.49 – 2.63) 
0.88 (0.38 – 2.06) 
 
0.7641 
 
– 
 
– 
Age  
<60 years  
≥60 years 
 
1.08 (0.47 – 2.48) 
0.93 (0.40 – 2.13) 
 
0.8494 
 
– 
 
– 
Primary tumour     
Site of primary tumor  
   Rectum 
   Colon / recto–sigmoid 
 
1.28 (0.43 – 3.78) 
0.78 (0.26 – 2.33) 
 
0.6504 
 
– 
 
– 
Lymph node status  
   Positive  
   Negative  
 
0.72 (0.16 – 3.23) 
1.38 (0.31 – 6.21) 
 
0.6788 
 
– 
 
– 
Histological grade 
   High grade 
   Low grade   
 
1.25 (0.35 – 4.35) 
0.80 (0.23 – 2.83) 
 
0.7324 
 
– 
 
– 
Adjuvant therapy  
   Yes 
   No   
 
1.05 (0.35 – 3.13) 
0.95 (0.32 – 2.86) 
 
0.9274 
 
 
– 
 
– 
Liver metastasis     
Number of lesions at presentation  
   Solitary  
   Multiple 
 
0.41 (0.15 – 1.11) 
2.44 (0.90 – 6.67) 
 
0.0797 
 
0.51 (0.19 – 1.42) 
1.96 (0.70 – 5.26) 
 
0.1985 
Mean baseline lesion size 
   <20 mm 
   ≥20 mm 
 
1.63 (0.65 – 4.06) 
0.61 (0.25 – 1.54) 
 
0.2957 
 
– 
 
– 
Preoperative therapy administered 
   CAPOX+bev / FOLFOX+bev  
   FOLFIRI+bev 
 
0.91 (0.36 – 2.31) 
1.10 (0.43 – 2.78) 
 
0.8476 
 
– 
 
– 
Cycles of preoperative therapy  
   ≤6 cycles 
   >6 cycles 
 
0.67 (0.30 – 1.51) 
1.49 (0.66 – 3.33) 
 
0.3315 
 
– 
 
– 
Interval between last bevacizumab 
dose and resection 
   <70 days 
   ≥70 days 
 
 
1.03 (0.44 – 2.38) 
0.97 (0.42 – 2.27) 
 
 
0.9488 
 
 
– 
 
 
– 
HGP 
≥50% replacement  
   ≥50% desmoplastic  
 
0.29 (0.12 – 0.67) 
3.50 (1.49 – 8.20) 
 
0.0040 
 
0.33 (0.14 – 0.80) 
3.03 (1.25 – 7.14) 
 
0.0135 
 
Footnote: For each variable tested, we present the odds ratio in both directions e.g. male vs female 
(HR=1.14) and its reverse, female vs male (HR=0.88), etc.  
 
bev, bevacizumab; CAPOX, capecitabine and oxaliplatin; FOLFOX, infusional 5–fluorouracil and 
oxaliplatin; FOLFIRI, infusional 5–fluorouracil and irinotecan.  
 
Supplementary Table 9 Analysis for differences in characteristics between 
patients with a predominant replacement HGP and patients with a predominant 
desmoplastic HGP 
 
Analysis was performed on 89 patients from MUHC that received preoperative therapy with 
bev–chemo or chemotherapy alone. Clinical characteristics were compared between 38 
predominant replacement HGP patients and 51 predominant desmoplastic HGP patients. The 
χ2 test was used to determine statistical significance. 
 
 Total number 
of patients 
Number of 
replacement 
patients (%) 
Number of 
desmoplastic 
patients (%) 
P–value 
Demographics     
Gender  
 Male 
 Female 
 
56 
33 
 
28 (50) 
10 (30.3) 
 
28 (50) 
23 (69.7)  
 
0.070 
 
Age  
 <60 years 
 ≥60 years 
 
35 
54 
 
15 (42.9) 
23 (42.6) 
 
20 (57.1) 
31 (57.4)  
 
0.980 
Primary tumour     
Primary tumour site 
 Rectum 
 Recto–sigmoid 
 Colon 
 
20 
17 
32 
 
7 (35) 
9 (52.9) 
22 (68.8) 
 
13 (65)  
8 (47.1) 
10 (31.2) 
 
0.544 
Lymph nodes 
 Positive 
 Negative    
 
44 
14 
 
20 (45.5) 
5 (35.7) 
 
24 (54.5) 
9 (64.3)  
 
0.522 
Histological grade 
 High grade 
 Low grade 
 
6 
55 
 
4 (66.7) 
20 (36.4) 
 
2 (33.3) 
35 (63.6)  
 
0.149 
Treated with adjuvant 
therapy 
 Yes 
 No 
 
  
16 
72 
 
 
8 (50) 
30 (41.7) 
 
 
8 (50) 
42 (58.3) 
 
 
0.543 
Liver metastasis      
Number of lesions at 
presentation 
             No lesion* 
 Solitary lesion  
 Multiple lesions 
 
 
3 
27 
59 
 
 
3 (100) 
8 (29.6) 
27 (45.8) 
 
 
0 (0) 
19 (70.4) 
32 (54.2) 
 
 
0.046 
Mean baseline lesion size 
 <20 mm 
 ≥20 mm 
 
25 
56 
 
9 (36) 
23 (41.1) 
 
16 (64) 
33 (58.9) 
 
0.666 
Therapy administered 
            FOLFOX 
            FOLFIRI 
            FOLFIRINOX 
            5–FU 
            FOLFOX + bev 
            FOLFIRI + bev 
 
24 
1 
2 
1 
49 
12 
 
11 (45.8) 
0 (0) 
1 (50) 
0 
19 (38.8) 
7 (58.3) 
 
13 (54.2) 
1 (100) 
1 (50) 
1 (100) 
30 (61.2) 
5 (41.7) 
 
0.679 
 
Table continues overleaf 
Supplementary Table 9 continued 
 
Cycles of preoperative 
therapy 
 ≤6 cycles 
 >6 cycles 
 
 
62 
27 
 
 
26 (41.9) 
12 (44.4) 
 
 
36 (58.1) 
15 (55.6) 
 
 
0.826 
Interval between last therapy 
dose and resection 
 <70 days 
 ≥70 days 
 
 
47 
38 
 
 
15 (31.9) 
21 (55.3) 
 
 
32 (68.1) 
17 (44.7) 
 
 
0.030 
 
Footnote: *Three patients were administered therapy prior to detection of liver metastases: 
one patient was receiving adjuvant bev-chemo when liver disease was detected, one patient 
was receiving bev-chemo for CRC lung metastasis when liver disease was detected and one 
patient was receiving adjuvant chemotherapy alone when liver disease was detected. 
FOLFOX, infusional 5–fluorouracil and oxaliplatin; FOLFIRI, infusional 5–fluorouracil and 
irinotecan; FOLFIRINOX, infusional 5–fluorouracil and irinotecan and oxaliplatin; 5–FU, 
infusional 5–FU only.  
 
  
Supplementary Table 10 Analysis for differences in characteristics between 
patients that received bev–chemo and patients that received chemotherapy 
alone 
 
Analysis was performed on 91 patients from MUHC. Clinical characteristics were compared 
between 62 patients that received pre–operative bev–chemo and 29 patients that received 
preoperative chemotherapy only). The χ2 test was used to determine statistical significance. 
 
 Total number 
of patients 
Number of  
bev–chemo 
patients (%) 
Number of 
chemo alone 
patients (%) 
P–value 
Demographics     
Gender  
 Male 
 Female 
 
57 
34 
 
37 (64.9) 
25 (73.5) 
 
20 (35.1) 
9 (26.5) 
 
0.393 
 
Age  
 <60 years 
 ≥60 years 
 
36 
55 
 
25 (69.4) 
37 (67.3) 
 
11 (30.6) 
18 (32.7) 
 
0.828 
Primary tumor     
Primary tumour site 
 Rectum 
 Recto–sigmoid 
 Colon 
 
21 
17 
53 
 
12 (57.1) 
10 (58.8) 
40 (75.5) 
 
9 (42.9) 
7 (41.2) 
13 (24.5) 
 
0.206 
Lymph nodes 
 Positive 
 Negative 
 
45 
14 
 
35 (77.8) 
8 (57.1) 
 
10 (22.2) 
6 (42.9) 
 
0.129 
Histological grade 
 High grade 
 Low grade 
 
6 
55 
 
5 (83.3) 
38 (69.1) 
 
1 (16.7) 
17 (30.9) 
 
0.468 
Treated with adjuvant 
therapy 
 Yes 
 No 
  
 
18 
72 
 
 
13 (72.2) 
48 (66.7) 
 
 
5 (27.8) 
24 (33.3) 
 
 
0.652 
Liver metastases     
Number of lesions at 
presentation 
             No lesion* 
 Solitary lesion  
 Multiple lesions 
 
 
4 
27 
60 
 
 
2 (50) 
18 (66.7) 
42 (70) 
 
 
2 (50) 
9 (33.3) 
18 (30) 
 
 
0.695 
Mean baseline lesion size 
 <20 mm 
 ≥20 mm 
 
25 
56 
 
14 (56) 
41 (73.2) 
 
11 (44) 
15 (26.8) 
 
0.125 
Therapy administered            
            FOLFOX 
            FOLFIRI 
            FOLFIRINOX 
            5–FU 
 
75 
13 
2 
1 
 
50 (66.7) 
12 (92.3) 
0 (0) 
0 (0) 
 
25 (33.3) 
1 (7.7) 
2 (100) 
1 (100) 
 
0.019 
 
Table continues overleaf 
Supplementary Table 10 continued 
 
Cycles of preoperative 
therapy 
 ≤6 cycles 
 >6 cycles 
 
 
63 
28 
 
 
41 (65.1) 
21 (75) 
 
 
22 (34.9) 
7 (25) 
 
 
0.349 
Interval between last 
therapy dose & resection 
 <70 days 
 ≥70 days 
 
 
48 
39 
 
 
35 (72.9) 
26 (66.7) 
 
 
13 (27.1) 
13 (33.3) 
 
 
0.527 
 
Footnote: *Four patients were administered therapy prior to detection of liver metastases: one 
patient was receiving adjuvant bev–chemo when liver disease was detected, one patient was 
receiving bev–chemo for CRC lung metastasis when liver disease was detected and two 
patients were receiving adjuvant chemotherapy alone when liver disease was detected. 
FOLFOX, infusional 5–fluorouracil and oxaliplatin; FOLFIRI, infusional 5–fluorouracil and 
irinotecan; FOLFIRINOX, infusional 5–fluorouracil and irinotecan and oxaliplatin; infusional 5–
FU. 
 
 
  
Supplementary Table 11 Characteristics of 17 patients from whom samples of 
breast cancer liver metastasis were obtained 
 
 
Details of primary  
Age at diagnosis of primary breast cancer, median (range)  47 (36 – 77) 
Primary was resected, number of patients (%) 
Yes 
No 
 
15 (88.2) 
2 (11.8) 
Ductal or lobular histology, number of patients (%) 
 Ductal 
 Lobular  
 Mixed 
 
13 (76.5) 
3 (17.6) 
1 (5.9) 
T–stage, number of patients (%) 
 T1  
 T2  
 T3  
 T4  
 N/A  
 
6 (35.3) 
6 (35.3) 
2 (11.8) 
1 (5.9) 
2 (11.8) 
Lymph nodes, number of patients (%)  
 Positive 
 Negative 
 N/A 
 
9 (52.9) 
6 (35.3) 
2 (11.8) 
Treatment received prior to obtaining liver metastasis sample  
Form of treatment received, number of patients (%) 
 Endocrine therapy  
 Chemotherapy  
 Herceptin  
 Everolimus 
 Iressa  
 Zometa 
 
14 (82.4) 
12 (70.6) 
2 (11.8) 
1 (5.9) 
1 (5.9) 
1 (5.9) 
Details of liver metastasis sample  
Age when sample was obtained, median (range) 54 (43 – 81) 
Source of material, number of patients (%) 
 Resection  
 Autopsy 
 
11 (64.7) 
6 (35.3) 
Intrinsic subtype, number of patients (%)  
 Luminal A 
 Luminal B HER2 negative 
 Luminal B HER2 positive  
 HER2 positive (non–luminal) 
 Triple negative  
 
5 (29.4) 
5 (29.4) 
3 (17.7) 
0 (0) 
4 (23.5) 
 
Footnote: N/A, data not available. 
  
Supplementary Figure 11 
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Supplementary Figure 11 Expression of the Arp2/3 subunit ARPC3 in human liver metastases
a,b. Validation of anti-ARPC3 antibody staining specificity 
HT29 cells stably transfected with a control non-targeting shRNA (control shRNA) (a) or an ARPC3-targeted shRNA 
(shARPC3-3) (b) were prepared for FFPE sections and then stained using an anti-ARPC3 antibody (MABT95, 
Millipore). Loss of antigenicity in the knockdown cells (b) compared to the control cells (a) indicates that this antibody 
is specific for ARPC3. 
c-e. Examples of  ARPC3 staining in human liver metastasis specimens
Samples of human liver metastasis were stained using the anti-ARPC3 antibody.  c. ARPC3 staining in normal liver.  
ARPC3 staining is limited to Kuppfer cells and immune cells within the lumen of vessels (arrowheads) and staining is 
absent / weak in hepatocytes. d-f. ARPC3 staining in cancer cells (Can) of a replacement HGP CRCLM (d), a 
desmoplastic HGP CRCLM (e) and a replacement HGP breast cancer liver metastasis (BCLM) (f). Panel g shows a 
negative control, where the same staining  protocol was performed but the primary antibody was omitted. Can, cancer 
cells. Lv, normal liver parenchyma.  DS, desmoplastic stroma.
h. Quantification of ARPC3 staining in human liver metastasis specimens
The intensity of ARPC3 staining was scored in replacement HGP CRCLMs (n = 10),  desmoplastic HGP CRCLMs (n 
= 10) and replacement HGP BCLMs (n = 9).  Each data point on the graph is the intensity (H-score) for an individual 
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Supplementary Figure 12 
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Supplementary Figure S12 Preclinical model of advanced liver metastasis 
a. Macroscopic appearance of tumor formation in the left main lobe of the mouse liver after injection of 
HT29 cells.  b. Macroscopic appearance of a human CRC liver metastasis resected from a patient (picture 
is courtesy of Mr Ali Majeed). Scale bar, 5 mm (a) or 5 cm (b). Tumor is indicated by an asterisk. 
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Supplementary Figure 13 Knockdown of ARPC3 in HT29 cells does not alter cell proliferation
Proliferation of parental HT29 cells (Parent) and HT29 cells stably transduced with control shRNA, 
shARPC3-1, shARPC3-2 or shARPC3-3. The quantity of viable cells is expressed relative to the quantity 
measured at 24 hours ± SEM (n = 3 independent experiments). n.s., no significant difference (Student’s t-test). 
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Supplementary Figure 14 
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Supplementary Figure 14 Staining for CD31 in HT29 tumours treated with B20-4.1.1 and 
capecitabine in vivo
a-d. HT29 tumors with normal ARPC3 levels (Control shRNA) or  ARPC3 knockdown 
(shARPC3-3) were established in the livers of mice and treated with B20-4.1.1 plus capecitabine 
(BC) or vehicle (Vh) alone. Liver specimens harvested after two weeks of treatment were stained 
for CK20 to label tumor cells and CD31 to label blood vessels. Representative images of the 
tumour-liver interface are shown for Control shRNA tumors treated with Vh (a) or B/C (b) and for 
ARPC3 knockdown tumors treated with Vh (c) or BC (d). Dashed line in panels c and d indicates 
where the desmoplastic rim of the tumor meets the normal liver. Lv, normal liver. Scale bar, 60 μM.  
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Supplementary Figure 15 Knockdown of ARPC3 does not effect tumor burden or tumor vessel 
density in mice treated with capecitabine alone
a-c. Tumors with normal ARPC3 levels (Control shRNA) or ARPC3 knockdown (shARPC3-3) were 
established in the livers of mice. Mice were then treated with capecitabine (C) or vehicle alone (Vh) for two 
weeks followed by histopathological analysis of the liver tumors (n = 8 mice per group). Graph in a shows 
the % HGP per group ± SEM. Graph in b shows liver tumor burden expressed in terms of lesion area ± 
SEM. Graph in c shows tumor vessel density in terms of vessels per mm2 ± SEM. For statistical analysis, 
Mann Whitney U-test (panel a) or Student’s t-test (panels b,c) were used. **P<0.01. n.s., no significant 
difference.
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Supplementary Figure 16
D
iff
er
en
ce
 (A
1-
A
2)
Supplementary Figure 16 Difference in % HGP scores between observers for the intra-observer and 
inter-observer agreement of HGP scoring
Two observers scored the HGP (% replacement, % desmoplastic, % pushing) in 150 tissue sections of colorectal 
cancer liver metastasis. The graphs show the difference between the two % replacement scores for every case 
for the following comparisons:
a. intra-observer agreement: observer A first score (A1) minus observer A second score (A2), b. intra-observer 
agreement: observer B first score (B1) minus observer B second score (B2), c. inter-observer agreement: 
observer A first score (A1) minus observer B first score (B1) and d. inter-observer agreement: observer A second 
score (A2) minus observer B second  score (B2). 
Data points which lie on the red line indicate cases for which there was complete agreement between the two 
scores, whilst data points either side of the line are cases for which there was disagreement between the two 
scores. 
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Supplementary Figure 17 Bland-Altman plots for intra-observer and inter-observer agreement of HGP scoring
Two observers scored the HGP (% replacement, % desmoplastic, % pushing) in 150 tissue sections of colorectal cancer 
liver metastasis. Bland-Altman plots show the difference between the two % replacement scores plotted against the 
average of the two % replacement scores for the following comparisons:
a. Intra-observer agreement: observer A first score (A1) versus observer A second score (A2). Mean difference between 
scores (-0.033) and limits of agreement (-7.431 to 7.497). b. Intra-observer agreement: observer B first score (B1) 
versus observer B second score (B2). Mean difference between scores (-0.633) and limits of agreement (-15.663 to 
14.397). c. Inter-observer agreement: observer A first score (A1) versus observer B first score (B1). Mean difference 
between scores (-1.500) and limits of agreement (-22.88 to 19.88). d. Inter-observer agreement: observer A second 
score (A2) versus observer B second score (B2). Mean difference between scores (-2.167) and limits of agreement 
(-25.287 to 20.953). 
Bold dashed line indicates the mean difference between scores whilst the flanking dotted lines show the limits of 
agreement. Note: since a large proportion of the 150 data points in each graph have identical x and y co-ordinates, many 
of the data points depicted constitute multiple overlaping data points.  
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Supplementary Table 12 Results of the intra– and inter–observer agreement 
study for scoring the HGPs of liver metastases 
 
 
Measurement of intra–observer agreement for HGP scoring 
Comparison 
 
Correlation  
co–efficient  
Mean 
difference 
Limits of  
agreement 
Observer A (1st score) versus 
Observer A (2nd score) 0.9965  0.033  (–7.431 to 7.497) 
Observer B (1st score) versus 
Observer B (2nd score) 0.9866 –0.633 (–15.663 to 14.397) 
 
 
Measurement of inter–observer agreement for HGP scoring 
Comparison 
 
Correlation  
co–efficient 
Mean 
difference 
Limits of 
agreement 
Observer A (1st score) versus 
Observer B (1st score) 0.9715 –1.500  (–22.88 to 19.88) 
Observer A (2nd score) versus 
Observer B (2nd score) 0.9678 –2.167 (–25.287 to 20.953) 
 
 
 
 
 
Supplementary Table 13 Criteria for scoring the intrinsic subtypes of breast 
cancer  
 
Intrinsic subtype Criteria 
Luminal A ER and PgR positive 
HER2 negative 
Ki67 ‘low’  
Luminal B HER2–negative ER positive 
HER2 negative 
Ki67 ‘high’ 
Luminal B HER2–positive ER positive 
HER2 positive 
Any Ki67 
Any PgR 
HER2 positive (non–luminal) HER2 positive 
ER and PgR absent 
Triple negative ER negative 
PgR negative 
HER2 negative 
 
Footnote: Table was adapted from: Goldhirsch, A., et al. Personalizing the treatment of 
women with early breast cancer: highlights of the St Gallen International Expert Consensus on 
the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24, 2206–2223 (2013). ER, 
estrogen receptor; PgR, progesterone receptor. 
 
 
